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Extensive evidence support an association between arterial cardiovascular disease (CVD, i.e. 
myocardial infarction [MI] and ischemic stroke), and subsequent venous thromboembolism (VTE, i.e. 
deep vein thrombosis [DVT]) and pulmonary emboli [PE]). However, the mechanism behind the 
associations remains unclear. The aim of this thesis was to investigate the impact of ischemic stroke 
on VTE and to investigate potential shared risk factors for arterial CVD and VTE. 
 All papers in this thesis utilize data from the Tromsø Study. The study populations for Paper I, 
II and III were recruited from the fourth, fifth and sixth survey of the Tromsø study. In Paper IV, we 
recruited a subgroup participants with genetic information from the fourth survey of the Tromsø Study 
and from the second survey of the Nord-Trøndelag Health (HUNT) Study. Participants were followed 
from the first survey they attended to the date of an incident event (i.e. VTE, MI or ischemic stroke), 
the date of death or migration, or until end of follow-up in 2008/2012. 
 Ischemic stroke was associated with a transient increased risk of VTE, and the risk was 
particularly high for provoked events. The association persisted after adjusting for potential 
confounders, indicating that the stroke itself increased the VTE risk. We found no association between 
formation, presence or progression of atherosclerosis and VTE in time-varying analyses, indicating that 
atherosclerosis does not represent the missing link for the association between arterial CVD and VTE. 
Except for body mass index, none of the traditional cardiovascular risk factors increased the risk of 
VTE, and risk estimates for MI and VTE based on a single baseline measurement and repeated 
measurements corresponded well. Lastly, we showed that the association between a family history of 
MI (FHMI) and VTE is not explained by prothrombotic genotypes, and that the combination of FHMI 
and prothrombotic genotypes had an additive effect on VTE risk. 
 Our findings imply a strong and transient increased risk of VTE after ischemic stroke and that 
the association between arterial CVD and VTE cannot be explained by atherosclerosis. Of the well-
known cardiovascular risk factors, only age, obesity and FHMI are associated with VTE. The association 
between arterial CVD and subsequent VTE is only partly explained by shared risk factors. The remaining 
association is likely mediated by risk factors following the arterial cardiovascular event, such as 
immobilization and infection, and direct effects of the arterial cardiovascular event, such as activation 






Det er gode holdepunkter for en sammenheng mellom arteriell kardiovaskulær sykdom 
(hjerteinfarkt og iskemisk hjerneslag) og påfølgende risiko for venøs tromboembolisme (VTE, 
fellesbetegnelsen på dyp venetrombose [DVT] og lungeemboli [LE]), men mekanismen for denne 
sammenhengen er ukjent. Formålet med denne avhandlingen har vært å undersøke hvordan 
hjerneslag påvirker risikoen for VTE og å undersøke potensielle felles risikofaktorer for kardiovaskulær 
sykdom og VTE. 
 Artiklene i avhandlingen bruker data fra Tromsøundersøkelsen. Studiedeltakerne i artikkel I, II 
og III ble rekruttert fra den fjerde, femte og sjette undersøkelsen (Tromsø 4, 5 og 6). De inkluderte i 
artikkel IV besto av en undergruppe som fikk utført genetiske analyser. Disse deltok i Tromsø 4 eller i 
den andre Helseundersøkelsen i Nord-Trøndelag (HUNT 2). I samtlige artikler ble deltakerne fulgt fra 
første undersøkelse de deltok i til en kardiovaskulær hendelse eller VTE oppsto, til de døde eller flyttet, 
eller til studieslutt i 2008/2012. 
 Iskemisk hjerneslag ga en forbigående økt risiko for VTE, og risikoen var særlig høy for 
provosert VTE. Sammenhengen vedvarte etter justering for potensielle konfoundere, noe som 
indikerer at det var hjerneslaget, eller tilstander relatert til hjerneslaget, som økte risikoen for VTE. Det 
var ingen sammenheng mellom nydannelse, tilstedeværelse eller progresjon av aterosklerose og VTE i 
analyser med oppdaterte målinger, noe som tyder på at aterosklerose ikke kan forklare 
sammenhengen mellom kardiovaskulær sykdom og VTE. Foruten kroppsmasseindeks ga ingen av de 
tradisjonelle kardiovaskulære risikofaktorene økt risiko for VTE, og risikoestimater for hjerteinfarkt og 
VTE basert på én måling og repeterte målinger korresponderte godt. Vi viste også at sammenhengen 
mellom familiær predisposisjon for hjerteinfarkt (FHMI) og VTE ikke kunne forklares av gener som øker 
trombosetendensen, og at kombinasjonen av FHMI og protrombotiske gener hadde additiv effekt på 
risiko for VTE.  
 Våre funn tyder på at det er en midlertidig økt risiko for VTE etter iskemisk hjerneslag, og at 
assosiasjonen mellom kardiovaskulær sykdom og VTE ikke kan forklares av aterosklerose. Blant 
velkjente kardiovaskulære risikofaktorene var det bare alder, overvekt og FHMI som hadde 
sammenheng med VTE. Felles risikofaktorer kan dermed bare delvis forklare sammenhengen mellom 
kardiovaskulær sykdom og VTE. Resten av sammenhengen kan trolig forklares av at komplikasjoner 
etter den kardiovaskulære hendelsen, som for eksempel immobilisering og infeksjoner, øker risikoen 






AP  attributable proportion due to interaction 
APC  activated protein C 
BMI  body mass index 
CCA  common carotid artery 
CI  confidence intervals 
CRP  C-reactive protein 
CT  computed tomography 
CTPH  chronic thromboembolic pulmonary hypertension 
CVD  cardiovascular disease 
DALY  disability-adjusted life-years 
DVT  deep vein thrombosis 
ECG  electrocardiography 
ECM  extracellular matrix 
F  factor 
FHMI  family history of MI 
FVL  factor V Leiden 
HDL  high-density lipoprotein 
HR  hazard ratio 
HUNT  Nord-Trøndelag Health Study 
IMT  intima media thickness 
ICA  internal carotid artery 
ICD  International Classification of Diseases 
LDL  low-density lipoprotein 
LMWH  low-molecular-weight heparin 
MI  myocardial infarction 
MRI  magnetic resonance imaging 
OR  odds ratio 
PE  pulmonary embolism 
PTS  post-thrombotic syndrome 
PVD  peripheral vascular disease 
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PY  person-years 
RERI  relative excess due to interaction 
RCT  randomized controlled trial 
SI  synergy index 
SNP  single nucleotide polymorphism 
TF  tissue factor 
TFPI  tissue factor pathway inhibitor 
TPA  total plaque area 
UNN  University Hospital of North Norway 
VTE  venous thromboembolism 
vWF  von Willebrand Factor 
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Venous thromboembolism (VTE) is the collective term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE). DVT is the formation of a thrombus (i.e. “blood clot”) in the deep veins, 
typically in the large and deep veins of the lower extremities. Other more unusual sites of thrombus 
formation are the deep veins of the upper extremities, the vena cava, the portal vein, the mesenteric 
veins and the venous sinuses in the brain. Classical signs and symptoms of DVT include pain, swelling, 
edema, and redness of the affected extremity. PE is usually a complication of DVT and occurs when a 
thrombus in a deep vein detaches from its original site and travels with the bloodstream to the lungs, 
where it lodges and interrupts normal blood flow. However, recent studies suggest that PE can also 
occur without an associated DVT. 1, 2 Classical signs and symptoms of PE include chest pain, tachypnea, 
dyspnea, and coughing. In severe cases, PE can lead to circulatory collapse and death. VTE is usually 
treated with anticoagulant agents. These drugs prevent further thrombus formation, while the already 
existing thrombus is degenerated by innate fibrinolytic systems in the body. Severe cases can be life-
threatening (e.g. large PE), and treatment with thrombolytic agents, which breaks down the thrombus, 
may be necessary. Treatment type and duration depends on the type of VTE event and presence of 
provoking factors. 
 Arterial and venous thrombosis have traditionally been considered as two separate diseases, 
with different pathophysiology and treatments. In a case-control study from 2003, Prandoni and 
colleagues reported a higher prevalence of carotid plaques in patients with unprovoked VTE, compared 
with patients with provoked VTE and controls.3 Although later prospective studies did not show any 
association between atherosclerosis and subsequent VTE,4-6 the findings supported the hypothesis of 
an association between arterial and venous thromboembolic diseases. Several studies have reported 
an increased risk of VTE after myocardial infarction (MI).7, 8 The risk of VTE seemed to be highest the 
first year following the MI, and the risk of PE was higher than the risk of DVT.7 In addition, studies 
investigating the association between stroke and VTE found a high prevalence of VTE the first months 
after the stroke,9-11 and identified risk factors included severe strokes and lower limb paresis.12, 13 
Furthermore, studies have reported an increased risk of arterial thrombotic disease (both MI and 
stroke) after VTE, 14-16 and the risk remained elevated for 20 years after the VTE event.15 Thus, there is 
growing evidence of a bidirectional association between arterial and venous thromboembolic diseases. 
The mechanism behind the associations remains unclear, but shared risk factors, mediators and a 
direct causal interrelation have been proposed as possible mechanisms.15 
 Of the traditional cardiovascular risk factors, only age and obesity have consistently been 
associated with VTE.17-20 Diabetes, hypertension, dyslipidemia, and smoking have been associated with 
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VTE in some, but not all studies.20-25 It is uncertain if the conflicting results are a consequence of 
different study populations or different study designs. In addition, family history of MI (FHMI) have 
been shown to increase the risk of VTE in several studies,26-29 indicating that shared environmental risk 
factors or genetic disposition in certain families can cause both arterial cardiovascular disease (CVD) 
and VTE.  
Cardiovascular diseases are the most common cause of death globally,30, 31 and stroke is an 
important cause of disability.32 The health burden of these diseases is immense,33, 34 and it is of great 
importance to identify possible mechanisms behind the association between arterial CVD and VTE. 
Topics of the present thesis will be the relationship between arterial CVD and VTE, and the association 
between cardiovascular risk factors and VTE. 
 
1.1 Epidemiology of venous thromboembolism 
VTE is the third most common cardiovascular disease, after MI and stroke.18 The incidence in 
the general population is 1 to 2 per 1,000 per year,35, 36 and the incidence increases with increasing age 
to nearly 1% per year in those > 80.35, 37 The incidence of VTE is increasing, mainly because of a 
substantial increase in incidence of PE.35, 38 In the Tromsø Study, the age-adjusted incidence rates (IR) 
of VTE increased from 158 per 100,000 person-years (PY) in 1996/1997 to 210 per 100,000 PY in 
2010/2011, and IR of PE increased from 45 to 113 per 100,000 PY in the same period.35 However, the 
increasing incidence of PE, the minimal change in mortality and the decreased case-fatality points 
towards an increase in diagnosis of clinically insignificant PE or false-positive results,39 rather than a 
true increase in disease.40 Women of reproductive age have a higher incidence of VTE than men at the 
same age, whereas men have a higher incidence in the elderly.37, 41 This may relate to differential 
exposure to clinical risk factors by age and sex, such as pregnancy, puerperium, and use of oral 
contraceptives among younger women.37  
 Approximately two-thirds of VTE events are diagnosed as DVT alone, and one-third as PE with 
or without concurrent DVT.35, 42, 43 Studies including autopsy reports tend to report a higher proportion 
of PE.44 PE was previously believed always to be a complication of DVT, occurring when a part of a 
thrombus of the deep veins dislodged and embolized to the lungs. However, in up to 50% of patients 
with PE, no DVT is found with ultrasound or magnetic resonance imaging (MRI).1, 2, 45 Possible 
explanations are that the thrombus can dislodge completely, that a PE can have a cardiac origin or that 
the PE originates from local thrombus formation in the lungs.2, 46, 47 VTEs are classified as provoked or 
unprovoked, depending on the presence of environmental provoking factors at the time of the VTE 
event. The estimated proportion of provoked events varies with definitions of unprovoked and 
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provoked events, but most population-based studies have estimated that 50-60% of VTE cases are 
associated with a provoking factor.35, 36, 43 An additional classification of provoking factors into minor 
transient, major transient and persistent provoking factors have been suggested (Table 1). Unprovoked 
events occur in the absence of any provoking factor.48 The risk of recurrent VTE is lowest for those who 
experienced a VTE triggered by a major transient risk factors and highest for patients with unprovoked 
VTEs or VTEs triggered by a persistent risk factor.44 Minor transient provoking factors are associated 
with a 3-10-fold increased risk of VTE and 15% will get a  recurrent event after five years, while major 
transient risk factors are associated with a greater than 10-fold increased risk of incident VTE, and 3% 
recurrence after five years.49 
In addition to short-term complications such as symptoms of DVT or PE and acute death, VTE 
has several long-term complications. A recurrent VTE may occur at any time after an incident VTE, and 
around 30% of VTE patients will experience a recurrent event within the first 10 years after an incident 
event.50-52 The risk of recurrence is highest the first 6-12 months following an incident VTE,41, 52 and 
independent risk factors of recurrence include male sex, increasing body mass index (BMI), 
neurological disease with paresis and active malignancy.43, 52-55 Furthermore, a meta-analysis 
concluded that recurrent VTEs tend to occur as the same type of clinical event as the initial event, i.e. 
patients with an incident PE tend to suffer from a recurrent PE.56 Chronic pain, venous stasis, skin 
changes, skin ulcers and heaviness are symptoms of the post-thrombotic syndrome (PTS), occurring in 
20-50% of DVT patients.50, 51, 57 It is the most common complication of DVT and risk factors for 
developing PTS include increasing age and BMI, female sex, previous ipsilateral DVT and a proximal 
thrombus (as compared with more distal thrombi).57 Among patients with PTS, 4-10% develop severe 
Table 1. Categorization of provoked VTE events.  
Transient risk factors Persistent risk factors 
Minor Major  
• Surgery with general anesthesia < 30 
minutes 
• Admission to hospital for less than 
three days with acute illness 
• Confined to bed out of hospital for at 
least three days with acute illness 
• Estrogen therapy 
• Pregnancy and puerperium 
• Leg injury with reduced mobility for 
at least three days 
• Surgery with 
general anesthesia 
> 30 minutes 
• Confined to bed in 
hospital for at 
least three days 
with acute illness 
• Cesarean section 
 





(Adapted from Kearon et al, J Thromb Haemost 2016). 
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PTS.50, 51, 57A serious long-term complication of PE is chronic thromboembolic pulmonary hypertension 
(CTPH), caused by high blood pressure in the arteries of the lungs due to chronic obstruction. 
Pulmonary hypertension forces the right side of the heart to work harder than normal and can lead to 
right-sided heart failure. Hence, symptoms of CTPH include dyspnea, chest pain and symptoms of right-
sided heart failure (e.g. dependent edemas, increasing abdominal circumference due to ascites and 
nocturia). CTPH affects 1-4% of patients within two years after a first episode of symptomatic PE, and 
risk factors for CTPH are previous PE, younger age, unprovoked PE and larger perfusion defect at 
presentation.58, 59  
 VTE has major consequences for the affected individual and for the society. In a large 
Norwegian population-based cohort study, participants with VTE had higher rates of work-related 
disability compared with participants without VTE (crude IR were 37.5 vs. 13.5 per 1,000 PY, 
respectively). In age- and sex-adjusted analyses, the hazard ratio (HR) of work-related disability after 
VTE was 1.62 (95% confidence interval [CI] 1.29-2.04), and the risk was especially high after DVT (HR 
1.80, 95% CI 1.37-2.36).60 A systematic review on the global disease burden of VTE concluded that VTE 
was the leading cause of hospital-related disability-adjusted life-years lost (DALYs), being responsible 
for more DALYs lost than nosocomial pneumonia and adverse drug events.61 Furthermore, VTE is 
associated with high mortality and fatality. A recent study using data from the Tromsø study found an 
overall 1-year all-cause mortality rate of 29.9 (95% CI 25.7-34.8) per 100 PY in VTE patients, and a rate 
of 23.6 (95% CI 17.8-31.3) per 100 PY in cancer-free VTE patients.41  Reported 30-day all-cause mortality 
ranges from 6% to 10%, and 1-year all-cause mortality from 21% to 33%.36, 62 1-year all-cause mortality 
was approximately 60% in patients with cancer-associated VTE and 15% in cancer-free VTE patients, 
indicating that cancer itself is an important cause of death among VTE-patients.36, 41, 62 The 30-day case-
fatality was higher in patients with PE than DVT (15% vs. 9%), and higher in patients with VTE provoked 
by cancer (25%) compared with individuals with VTE provoked by other factors than cancer (7%).43  
 
1.2 Pathophysiology of venous thromboembolism  
In 1856, Rudolph Virchow postulated that abnormalities in blood flow (stasis), 
hypercoagulability of the blood and injury to the vessel wall could lead to thrombus formation.63  These 
factors are collectively termed Virchow’s triad, and they remain important and relevant for our 
understanding of thromboembolic diseases.  
Physiological hemostasis prevents blood loss after vessel damage. Primary hemostasis denotes 
the process of platelet activation and adhesion, and secondary hemostasis refers to the initiation of 
the coagulation cascade and fibrin formation. The coagulation cascade is a complex cascade of proteins 
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increasing (procoagulant proteins) and decreasing (anticoagulant proteins) the fibrin formation, which 
is the end product of the cascade and the main component of a venous thrombus. The coagulation 
cascade consists of the intrinsic, extrinsic and the common pathway (Figure 1). The pathways are 
multiple series of reactions where the activated form of a protein activates the next protein in the 
cascade. Tissue factor (TF), expressed in monocytes, monocyte-derived microvesicles and possibly by 
activated endothelial cells triggers the extrinsic pathway (TF and FVIIa), while cellular RNA and 
polyphosphate expressed by activated platelets and bacteria trigger the intrinsic pathway FXIIa, FXIa, 
FXIa, and FVIIIa). The common pathway consists of FXa, FVa, and thrombin (FIIa), which converts 
fibrinogen to fibrin.64 The coagulation cascade is regulated by different anticoagulant pathways. Tissue 
factor pathway inhibitor (TFPI) blocks FXa and the TF/FVIIa complex, activated protein C (APC) 
inactivates FVa and FVIIIa and antithrombin inhibits all procoagulant proteins.64 The coagulation 
cascade is thoroughly regulated, and disorders of the coagulation proteins can lead to excessive 
bleeding or thrombus formation. For example, an animal study showed that mice deficient in proteins 
of the extrinsic or common pathway die during embryonic development or shortly after birth. Further, 
Figure 1. A simplified figure of activation of the coagulation cascade. Pathological activation of the extrinsic 
pathway (FVIIa and TF) is via expression of TF in monocytes, monocyte-derived microvesicles and possibly by 
activated endothelial cells. Cellular RNA and polyphospate released by activated platelets and bacteria 




mice lacking one of the three major anticoagulants do not survive, indicating that all of the pathways 
are required to regulate the clotting cascade.65  
Under normal conditions, blood flows from arteries, through capillaries and returns to the 
heart via the veins. While the pressure is high in arteries, the veins are a low-pressure system in which 
the blood moves against gravity, and blood flow is maintained by skeletal muscle contractions 
squeezing blood through the veins while the venous valves prevent back-flow. In situations or 
conditions preventing normal function of the skeletal muscles and normal blood flow, a generalized 
venous stasis may occur. Immobilization, surgery, hospitalization, and pregnancy are all well-known 
risk factors for VTE that may cause reduced blood flow and stasis. A localized stasis in the venous valve 
pockets is likely to play an important role in the pathogenesis of VTE as autopsy and radiology studies 
have shown that venous thrombi originate in the venous valves.66 This is emphasized by the increased 
risk of DVT with increasing numbers of venous valves.67 Blood flowing past the venous valves creates 
a vortex flow in the valvular pockets, causing stasis and hypoxia in the bottom of the valves (Figure 2). 
Possibly, hypoxia activates the valvular endothelium, monocytes, and platelets, which further triggers 
the coagulation cascade.66, 68 In addition, platelets and leukocytes may be activated by malignancies or 
infection.69-71 
Plaque formation and plaque rupture play a key role in the pathogenesis of arterial CVD, but 
the role of vessel wall injury in the development of VTE is less clear. The vessel wall may be injured (for 
example due to trauma,72 surgery or central venous catheters) and cause thrombosis through exposure 
of TF and cellular RNA.73 However, a histological study found no evidence of endothelial damage for 
most thrombi.74 Although there is no direct injury, alterations in the valvular endothelium (due to 
hypoxia, as described above) and imbalance between pro- and anticoagulant factors may explain why 
 
Figure 2. The pathophysiology of thrombus 
formation in the venous valves. Due to 
vortexes, blood is trapped in recesses of the 
valves pockets. The hypoxia that accrues 
promotes prothrombotic processes in the 
endothelial cells, platelets (Plt) and 
leukocytes (monocytes [Mc] in particular). 
Activated monocytes and platelets bud off 
microparticles (MP) containing TF, which 
triggers the extrinsic pathway of the 
coagulation cascade. (Figure by Roy Lyså) 
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thrombi can occur.64  Brooks and colleagues showed that vascular endothelial proteins important for 
activation of protein C (endothelial protein C receptor and thrombomodulin) were increased in valvular 
pocket endothelium compared to endothelium of the vein lumen. Variations in the up and down-
regulation of anticoagulant proteins in valvular pockets may be associated with thrombus formation.75 
In addition, activated endothelial cells can downregulate the expression of endothelial protein C 
receptor and thrombomodulin, and upregulate expression of TF.76  
Hypercoagulability, or thrombophilia, is the term used for the increased tendency of thrombus 
formation. Thrombophilia can be inherited or acquired, and mechanisms include an increased 
concentration of procoagulant proteins, the presence of variant clotting proteins that are more 
procoagulant, decreased concentration or deficiency of anticoagulant proteins and/or decreased 
fibrinolysis.64 For example, a mutation in the F5 gene leads to a variant of FV (Factor V Leiden) that is 
more resistant to APC, and mutations causing antithrombin or protein C or S deficiency leads to 
reduced levels or functionality of the anticoagulant proteins (see Figure 1).77 
 
1.3 Risk factors of venous thromboembolism 
A risk factor can be defined as any attributes, characteristics or exposures of an individual that 
increases the likelihood of developing a disease or injury.78 VTE is considered a multicausal disease,79 
and several acquired and inherited risk factors have been described.80 The complex interactions 
between risk factors, causing VTE in some individuals, but not others, may be explained by the 
thrombosis potential model, first described in 1999.79 The model shows how combinations of different 
risk factors and provoking factors may cause the thrombosis potential to exceed the thrombosis 
threshold (Figure 3).  
The person in Panel A has an underlying thrombophilic trait (e.g. FVL), and risk is increasing 
with increasing age. Early in life, there is a major transient provoking factor (e.g. surgery), but the 
thrombosis potential does not exceed the thrombosis threshold. Later in life, the same person 
experiences another major transient provoking factor (e.g. acute illness with immobilization), the 
thrombosis potential rises above the threshold, and the person experiences a VTE. The thrombosis 
potential remains increased following the incident VTE event, and a subsequent minor provoking 
factor (e.g. estrogen therapy) is enough to cause a recurrent VTE. Note that the combination of age 
and FVL exceeds the additive effects of age and FVL, indicating positive interaction between the two 
risk factors. In Panel B, there is no underlying thrombophilic trait, and neither a minor nor a major 
provoking factor is enough to push the potential over the threshold early in life. Later in life, however, 
the person gets a persistent provoking factor (e.g. cancer). Although the persistent provoking factor 
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alone is not enough for the potential to exceed the threshold for this person, an additional (minor or 
major) transient factor pushes the potential higher than the threshold, and the person experiences an 
incident VTE.  
Minor transient provoking factors are associated with low risk of incident VTE, but high risk of 
recurrent VTE,49 indicating that subjects who experience an incident VTE triggered by a minor risk 
factor have a higher baseline risk (i.e. their baseline thrombosis potential is closer to the thrombosis 
threshold) and thereby a higher risk of recurrent VTE. The same could be true for patients with 
unprovoked VTE. Conversely, major transient provoking factors are associated with a high risk of 
incident VTE because the trigger is strong enough to push the thrombosis potential over the 
thrombosis threshold, independent of the baseline risk. However, when the risk factor is removed and 
the thrombosis potential is back to normal, the risk of recurrence is low.49, 81  
 
Figure 3. The thrombosis potential model. The blue line represents a risk factor that increases over time, e.g. 
age, and the green line represents risk factors that are stable over time, e.g. Factor V Leiden (FVL) or other 
thrombofilic traits. The yellow line represents the combination of age and FVL and red bars represent 
provoking factors. Early in life, the provoking factor is not enough to reach the thrombosis threshold and the 
subjects remains free of VTE. Later in life, provoking factors may cause the thrombosis potential to exceed 
the thrombosis threshold, dependent on the subject’s baseline potential (i.e. baseline risk). The subjects may 
experience an incident or recurrent VTE. (Adapted from Roach et al, Journal of Thrombosis and Haemostasis 
2015 and Rosendaal, Lancet 1999) 
18 
 
1.3.1 Hereditary risk factors 
There is a high heritability of VTE. A family history of VTE is an independent risk factor for VTE,82 
and family and twin studies indicate that genetic risk factors account for 50-60% of VTE risk.83-86 
Inherited thrombophilia can be caused by two main mechanisms: gain-of-function of procoagulant 
factors and loss-of-function of anticoagulants.77 The following section will focus on the different 
mechanisms of inherited thrombophilia and exemplify how and to what extent well-known 
prothrombotic genotypes affect the risk of VTE. 
 Gain-of-function is caused by mutations in genes coding for procoagulant proteins, leading to 
increased production and concentration of a normal protein (e.g. prothrombin G20210A and non-O 
blood type), impaired down-regulation of a normal protein (e.g. FVL) or, rarely, synthesis of a 
hyperactive protein (factor IX Padua).77 The rs1799963 mutation in the F2 gene, more commonly 
known as prothrombin G20210A, leads to a high plasma level of prothrombin (see Figure 1),87 and 
possibly reduced inactivation of factor FVa by APC.88 The prothrombin G20210A variant is associated 
with a 1.5 to 3-fold increased risk of VTE,87, 89 and it is present in 2% of the normal population.90 The 
non-O blood type is one of the most common genetic risk factors for VTE, and the risk is probably 
mediated through increased levels of von Willebrand factor (vWF) and FVIII.91 Non-O blood type is 
associated with 1.5 to 2-fold increased risk of VTE,89, 92 and the variant is present in about 60% of the 
Norwegian population.93 An example of a mutation causing impaired down-regulation of a normal 
protein is the rs6025 mutation in the F5 gene, commonly known as FVL. The mutation leads to a 
missense mutation (the amino acid arginine is replaced by glutamine) in FV, leading to APC-resistance 
and consequently reduced inactivation of FVa.94 The mutation is present in about 5% of the healthy 
population,95, 96 and is associated with a 2.2 to 3-fold increased risk of VTE.89, 96, 97 A mutation in the F9 
gene, causing hyperfunctional FIX (8-fold the normal activity), was detected in an Italian family with 
juvenile VTE.98 The mutation has been named factor IX Padua, and has not been found in other cohorts 
of patients with VTE.77 
 The other mechanism of inherited thrombophilia is loss-of-function of the anticoagulant 
proteins (see Figure 1). These mutations are associated with a higher risk of VTE than the gain-of-
function mutations, but are less frequent.99 Deficiency in antithrombin, protein S or protein C is caused 
by reduced concentration and/or low protein activity.77 The prevalence of antithrombin deficiency is 
approximately 0.02% in the general population and up to 2% in VTE patients.90 The prevalence of 
protein S and protein C deficiency is about 0.2% in the general population and 2-3.4% in VTE patients.90 
Deficiency of the anticoagulant proteins are associated with a 10 to 20-fold increased risk of VTE.100, 101 
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 In 1965, Olav Egeberg described the first family with an identified thrombophilia, caused by 
antithrombin deficiency.102 During the 1980s and 1990s, more prothrombotic genetic variants, such as 
protein C and S deficiency, FVL and prothrombin G20210A, were discovered.87, 94, 103 Since then, 
genome-wide association studies (GWAS) have allowed identification of more single nucleotide 
polymorphisms (SNPs) associated with VTE.99, 104 Although the new SNPs display weaker associations 
with VTE, the SNPs may be of clinical significance if they interact with other risk factors of VTE, giving 
supra-additive risk estimates. For example, a recent study reported that the combinations of cancer 
and variants in the F5 gene (rs6025 and rs4524) yielded a synergistic increase of VTE risk.105 
Furthermore, the combination of these may improve prediction models of VTE.106 In 2013, de Haan 
and colleagues proposed the inclusion of selected SNPs in a VTE prediction model. The genetic score 
based on the 5 SNPs most strongly associated with VTE performed as well as the score of 31 SNPs, and 
combining the genetic and non-genetic risk scores improved the diagnostic accuracy of the prediction 
model.106 Nonetheless, the authors concluded that subgroups of high-risk persons, in whom genetic 
profiling will be cost-effective, must be identified for the genetic risk scores to become clinically 
relevant.106  
In total, 17 genes have been robustly demonstrated to be associated with VTE,107 however, 
they only explain 15-20% of the VTE heritability.85 This suggests that much remains to be done to 
understand the genetics and epigenetics of VTE.  
 
1.3.2 Acquired risk factors 
There are several well-established acquired risk factors for VTE. These include, but are not 
limited to, age, obesity, cancer, hospitalization, surgery, trauma, acute medical conditions, 
immobilization, pregnancy and puerperium, and estrogen treatment.108-110 Cardiovascular risk factors 
and risk of VTE will be discussed in section 1.3.3. 
 Advancing age is a strong risk factor for VTE, and the incidence increases with increasing age. 
Studies have reported an annual incidence around 800 per 100,000 in those ≥ 80.35, 37 In a sex-adjusted 
analysis, people > 70 years had an 11-fold increased risk of VTE (HR 10.5, 95% CI 7.8-14.2) compared 
with those < 50 years of age.17 The reasons for the increased risk in the elderly is not fully understood. 
Although the increased risk cannot be attributed to a higher incidence of cancer,111 cumulative 
clustering of other risk factors with increasing age may explain some of the excess risk. Increased levels 
of D-dimer, C-reactive protein (CRP), vWF, tissue plasminogen activator, FVIII and fibrinogen in the 
elderly may indicate increasing activation of blood coagulation and inflammation.112-114 Further, the 
increased risk in the elderly may be attributed to age-related degeneration of venous valves and 
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decreased compliance of the vein walls.66 Lastly, some of the excess risks in the elderly may be due to 
reduced muscle strength and a less effective skeletal-muscle pump.115 
 Obesity, defined by the World Health Organization (WHO) as BMI ≥ 30 kg/m2,116 is associated 
with a 2 to 3-fold increased risk of VTE compared with subjects with BMI < 25 kg/m2.17, 117 Using a 
population-based cohort, Heit and colleagues estimated that 33% of unprovoked VTEs could be 
attributed to overweight and obesity.118 Other measures of obesity, such as waist circumference (WC), 
hip circumference and waist-hip ratio, were also associated with increased risk of VTE.119, 120 In fact, 
WC showed higher risk estimates for VTE and identified more subjects at risk of VTE than BMI.119, 121 In 
addition, weight gain itself has been shown to increase the risk of VTE, especially in already obese 
subjects.122 As obesity is associated with elevated iliofemoral venous pressure123 and because venous 
flow in the lower extremities differs significantly between healthy obese and non-obese individuals, 
obesity-induced stasis has been suggested as a mechanism behind the association between obesity 
and VTE.124 Other possible mechanisms include obesity-driven chronic inflammation and impaired 
fibrinolysis.125-127  
In 1865, Armand Trousseau described an association between cancer and VTE. Since then, 
many studies have confirmed the association. Subjects with cancer have a 4 to 7-fold increased risk of 
VTE compared with subjects without cancer,128-130 and overall, approximately 20% of VTE cases could 
be attributed to malignancy.109 Risk of VTE is highest the initial 3-12 months after cancer diagnosis,128, 
130, 131 and several scientists argue that therapeutic interventions (e.g. surgery or chemotherapy) and 
hospitalizations are possible explanations for this.128, 132 Risk of VTE seems to vary among different 
types of cancer and cancer stage, with risks being highest for patients with cancers of the pancreas, 
brain, and lung,130, 133 and for patients with more advanced cancer.128, 132, 134 Of note, HRs of VTE were 
substantially reduced when competing risk by death was taken into account.131 This suggested that the 
high risk of VTE in certain cancer types may be due to high mortality in these cancers and that the 
apparent high risk immediately after diagnosis is explained by poor prognosis.131 Furthermore, the risk 
of VTE was similar in the periods six months before and six months after cancer diagnosis, and as it is 
reasonable to assume that subjects were unexposed to treatment-related factors in the prediagnostic 
period, the study implies that cancer itself is an important risk factor for VTE.131 The pathophysiology 
of cancer-related VTE can be explained by Virchow’s triad. Cancer causes a hypercoagulable state with 
increased activation of the coagulation cascade,135 tumor invasion or cancer treatment can lead to 
vessel wall injury,136 and tumors can cause venous stasis by direct compression of blood vessels.137 
 Hospitalization is a strong risk factor for VTE. One study found that the age- and sex-adjusted 
incidence rate of VTE in hospitalized patients were 960 per 10,000 PY, while the incidence rate in the 
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community was 7.1 per 10,000 PY.138 Furthermore, calculations showed that 59% of VTE cases could 
be attributed to institutionalization, and hospitalization for surgery and for medical conditions 
accounted for similar proportions of the cases (24% and 22%, respectively).109 Several risk factors can 
be present during hospitalization, such as surgery, acute medical conditions, and immobilization. As 
previously mentioned, surgery is categorized as minor or major transient provoking factors, depending 
on the type of surgery and duration of general anesthesia. Major surgery, broadly defined as 
operations requiring ≥ 30 minutes of general anesthesia, carries a high risk of VTE. Procedures 
conferring highest risk of VTE were invasive neurosurgery (HRs ranging from 4 to 40) and orthopedic 
surgery (HRs ranging from 3 to 12).129, 139 Several acute medical conditions are associated with 
increased risk of VTE, including myocardial infarction and stroke (discussed in section 1.4), infections, 
respiratory diseases, congestive heart failure, and autoimmune diseases.8, 129, 140-143 Institutionalization 
due to an acute medical condition was associated with an 8-fold increased risk of VTE (HR 8.0, 95% CI 
4.5-14.2).129 Although risk assessment models (e.g. the Padua Prediction Score for medical patients),144 
have been developed to help discriminate between patients at high and low risk of VTE, studies show 
that only 60-65% of surgical patients and 35-40% of medical patients with high risk of VTE received 
appropriate prophylaxis.145-147 
 Immobilization leads to stasis, which is one of the main causes of VTE. Immobilization 
accompanies many surgical and medical conditions and probably mediates some of the association 
between these conditions and VTE. The definition of immobilization and strengths of risk estimates 
varies. In one study, immobilization, defined as total confinement to bed and/or armchair, was 
associated with a 6-fold increased risk of VTE (HR 5.6, 95% CI 2.3-13.7).148 However, another study 
found a 1.8-fold (HR 1.76, 95% CI 1.27-2.44) increased risk of VTE in patients with total body 
immobility.149 In the Tromsø study, immobilization, defined as bedrest for at least three days, Eastern 
Cooperative Oncology Group (ECOG) score of 4 or other specified immobilizing factors, was associated 
with a 38-fold increased risk of VTE. Immobilization and infection had synergistic effects on VTE, 
yielding an odds ratio (OR) of 141 (95% CI 66-298).141 In a study from 1972, Warlow and colleagues 
reported that stroke patients who did not receive anticoagulation had a venous thrombus in 60% of 
the paralyzed legs and in 7% of non-paralyzed legs.150 Although some degree of immobilization occur 
during prolonged travel, the association between VTE and prolonged travel is controversial.80, 148, 149 A 
case-control study reported that traveling for more than four hours was associated with a 2-fold 
increased risk of VTE, and the risk was similar in those traveling by plane, car, bus or train. This indicates 




1.3.3 Cardiovascular risk factors 
Shared risk factors have been proposed as a possible mechanism for the association between 
arterial CVD and VTE.152 Many studies have investigated the association between traditional 
cardiovascular risk factors and VTE, but the results are conflicting. Only age, obesity and FHMI have 
consistently been associated with VTE.17-19, 27, 28, 117 Age and obesity as risk factors for VTE have been 
discussed in detail, and the following section will focus on some of the remaining cardiovascular risk 
factors and risk of VTE. 
Results regarding the association between sex and incident VTE are conflicting. While some 
studies have shown similar incidence and risk of VTE in men and women,17, 37, 153 others have found an 
overall higher incidence and risk of VTE among men.19, 20, 37, 43 As previously mentioned, women of 
reproductive age have a higher incidence of VTE than men at the same age, whereas men have a higher 
incidence in the elderly.36, 37 This may relate to differential exposure to clinical risk factors by age and 
sex, such as risk factors related to pregnancy and contraception, among younger women.37 In a 
population-based case-control study, Roach and colleagues showed that the risk of incident VTE was 
twice as high in men as in women when female reproductive risk factors were taken into account, 
supporting that male sex is a risk factor for incident VTE.154 Furthermore, because the age-specific 
incidence is different in men and women, the risk related to the sex would depend on the age 
distribution of the study population. Lastly, the sex difference in risk of VTE may partly be explained 
by an increased risk of VTE with increasing body height.155, 156  
Evidence support that there is no association between hypertension and VTE. One case-control 
study reported a reduced risk of VTE in subjects with blood pressure in the highest quintile,28 and a 
cohort study reported a HR of 1.51 (95% CI 1.13-2.01) in men with diastolic blood pressure in the 
highest quartile.20 Nevertheless, most studies found no association between hypertension and VTE.17-
19  
Dyslipidemia is the collective term for abnormal levels of lipids (i.e. high levels of low-density 
lipoprotein [LDL], low levels of high-density lipoprotein [HDL] and/or high levels of triglycerides) in the 
blood.  Although some case-control studies have reported an association between dyslipidemia and 
VTE,22, 25 the majority of studies show no association with VTE.17-20, 157 The positive results in the case-
control studies may be due to limitations of the study design, such as reverse causation, selection bias 
or unmeasured confounders. 
Diabetes is a strong risk factor for arterial CVD, but not for VTE. A few studies have reported 
an association between diabetes and VTE, however, authors were not able to adjust for BMI.19, 21 The 
majority of studies found no association between diabetes and VTE when analyses were adjusted for 
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BMI.17, 18, 20, 23, 158, 159 The metabolic syndrome is a cluster of cardiovascular risk factors, including 
abdominal obesity, insulin resistance, hypertension and dyslipidemia,160 associated with increased risk 
of CVD and mortality.161 The syndrome has been associated with unprovoked VTE162 and recurrent 
VTE.163 However, two studies demonstrated that the risk of VTE was mediated by abdominal obesity 
and that none of the other components of the metabolic syndrome, alone or in cluster, was associated 
with increased risk of VTE.164, 165  
Some studies found an association between current/former smoking and VTE,24, 166, 167 and 
some found a dose-dependent association,20, 167-169 whereas several studies have failed to find an 
association between smoking and VTE.17-19, 28 A meta-analysis from 2013 reported  a 1.3-fold (95% CI 
1.24-1.37) increased risk of VTE in current smokers compared with never smokers, and a dose-
dependent association with 6% increased risk of VTE per additional pack-year, in models adjusted for 
BMI. The risk was increased for both unprovoked and provoked VTE.170 In contrast, a large Danish 
cohort study found an association between current smoking and provoked VTE, but not between 
smoking and unprovoked VTE or VTE provoked by provoking factors other than cancer.167 Furthermore, 
a study including participants from the Tromsø study reported an association between heavy smoking 
and provoked VTE. However, the association disappeared when a cause-specific model was applied 
(i.e. eliminating possible mediation by MI and cancer), suggesting that smoking-attributable diseases 
or other predisposing factors may mediate the apparent association between smoking and VTE.171 
Proposed mechanisms for the association between smoking and VTE include a smoking-induced 
procoagulant state, increased inflammation, and reduced fibrinolysis.170, 172 
Results regarding a possible association between physical activity and VTE are diverging. Some 
studies have shown a protective effect of physical activity on risk of VTE,173 and provoked VTE in 
particular.18 Some studies found an increased risk of VTE in those physically active,18, 174 while other 
studies have failed to find an association.19, 20, 175 In several of the studies, authors were unable to adjust 
for BMI.18-20 The lack of standardized assessment methods and definitions of physical activity 
complicates the interpretation of the existing results. Plausible mechanisms for a beneficial effect of 
physical activity might be improved function of the calf muscle pump function and increased 
fibrinolysis.176, 177  
Socioeconomic status, often measured by education, occupation and income, is closely related 
to health, and coronary heart disease in particular.178, 179 However, few studies have investigated the 
association between education level and VTE, and results are conflicting.19, 20 
Growing evidence suggests an association between FHMI and VTE. In 2008, Brækkan and 
colleagues were the first to address the association and found a 1.3-fold increased risk of VTE in a 
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multivariable-adjusted analysis (HR 1.27, 95% CI 1.01-160).26 One case-cohort and one case-control 
study confirmed the association with equal magnitude of risk estimates,28, 29 but the study stratifying 
by ethnicity found no association between FHMI and VTE in blacks (not further specified).29 The 
association between FHMI and VTE could potentially be mediated by an increased risk of MI. To 
address this problem, the authors in one study applied a cause-specific model and found a 1.3-fold 
increased risk of VTE in analyses adjusted for cardiovascular risk factors.27 The risk was particularly high 
for unprovoked VTE and increased with increasing numbers of affected relatives, which pointed 
towards shared environmental or genetic risk factors.26, 27 In contrast, subjects with a parental history 
of MI had a 3% increased risk of VTE (standardized incidence ratio of 1.03, 95% CI 1.01-1.04) in a large 
registry-based study.180 However, this study defined FHMI as MI in a first-degree relative regardless of 
the relative’s age at the event, whereas the other studies defined FHMI as MI in a first-degree relative 
below the age of 60. This, in addition to limited information on potential confounders, might explain 
the diverging results.   
Results regarding the associations between many of the cardiovascular risk factors and VTE are 
inconsistent. Overall, the majority of studies that found an association between cardiovascular risk 
factors and VTE were retrospective,21, 22, 25, 28, 173 whereas most prospective studies reported no 
association.17-20, 23, 159, 175 In most cohort studies, risk factors are assessed at baseline and related to 
outcomes occurring several years later. However, the status of a risk factors can change over time. For 
example, people can gain weight, stop smoking or get increased blood pressure during follow-up. 
Random measurement errors, temporary fluctuations, and changes in exposure over time generally 
lead to regression dilution bias,181 a phenomenon that results in an underestimation of the true 
association between exposure and outcome. As most of the cardiovascular risk factors are modifiable, 
changes during follow-up may have influenced the risk estimates of VTE cohort studies. Thus, we 
cannot exclude that there are weak associations between the cardiovascular risk factors and VTE, 
which we are unable to detect because of regression dilution bias. Regression dilution bias can be 
addressed by performing time-varying analyses (requires repeated measurements of all participants) 
or correct the risk estimates by a regression dilution ratio (requires repeated measurement of a 
subsample of the participants).182, 183 Using the latter approach, a previous study reported that a single 
baseline measurement of cholesterol and diastolic blood pressure resulted in a 47% and 76% 





1.4 Association between arterial cardiovascular disease and venous 
thromboembolism 
1.4.1 Arterial cardiovascular disease and risk of venous thromboembolism 
Arterial CVD and VTE have traditionally been considered as separate diseases. However, 
several studies performed during the last decades have pointed towards a potential bidirectional 
association between arterial CVD and VTE.11, 14-16, 185  
 A growing amount of evidence support an association between arterial CVD and subsequent 
VTE. Some studies investigating the association between MI and VTE show that patients with MI have 
a 1.3 to 1.5-fold higher risk of subsequent VTE.5, 7, 186 However, others have failed to find a 
relationship,187, 188 and one cohort study reported a reduced risk of VTE in patients with arterial events.6 
When the positive associations were investigated in detail, the risk of VTE was higher when the MI 
occurred less than three months before the VTE diagnosis, as compared with more than three 
months.7, 185 Furthermore, the risk was higher for PE than DVT,7, 185 and reported risks for unprovoked 
and provoked events were similar.7, 186 The results from these studies must be interpreted with caution, 
as many of them are retrospective and therefore unable to determine causality,7, 185-188 or because they 
have limited validation of CVD, VTE, and potential confounders.7, 185, 186, 188  
Furthermore, there seems to be a strong association between stroke and subsequent VTE. A 
study in which stroke patients were screened for thrombosis (using 125I fibrinogen) showed that around 
50% developed DVT within 2 weeks in absence of thromboprophylaxis,189 and a small cohort study of 
111 Asians detected DVT in 30% of patients after 10 days and in 45% of patients after 30 days.10 In the 
CLOTS trial, which investigated the effect of compression stockings in stroke patients, DVT was 
detected in 11.4% of patients after eight days, and 14.5% after 28 days.9 In a large case-control study, 
the OR of VTE was 1.31 (95% CI 1.17-1.48) in patients with a previous hospital diagnosis of stroke, and 
the risk was substantially higher if the stroke occurred within three months before the VTE (OR 4.41, 
95% CI 2.92-6.65).7 Risk factors for developing VTE included severe stroke,11, 13 lower limb paresis,12, 190 
age10, 190 and CRP.191 VTE after stroke is associated with high mortality. PE account for 13-25% of early 
deaths after stroke,189 and one study showed that sudden death occurred in 50% of PE patients with 
previous stroke.192 There are several evident limitations potentially explaining the imprecise results, 
including different study designs, small study populations with different ethnicity, limited validation of 
exposures, outcomes and potential confounders and missing information on the use of anticoagulant 
prophylaxis (yes/no, type and duration). Limiting data exists regarding the association between 
ischemic stroke and VTE in the general population. 
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 Few studies have investigated the association between peripheral vascular disease (PVD) and 
VTE. An autopsy study, which found no association between coronary thrombosis and VTE, found an 
increased risk of VTE in relation to the presence of PVD (OR 1.7, 1.6-1.9).188 A retrospective cohort of 
302 patients and controls investigated the risk of VTE after arterial events but did not give a specific 
risk estimate after PVD due to a low number of outcomes (n=1).193  
 
1.4.2 Atherosclerosis and venous thromboembolism 
Atherosclerosis is characterized by the presence of atherosclerotic plaques. The vessel walls 
have three concentric layers - intima, media, and adventitia. The intima is the innermost layer (i.e. 
closest to the vessel lumen) and consists of endothelial cells and underlying extracellular matrix (ECM). 
It is separated from the media, which mainly consists of smooth muscle cells and ECM, by an elastic 
membrane. Atherosclerotic plaques are intimal lesions and are considered as a chronic inflammatory 
response of the arterial wall to endothelial injury.194, 195 The pathogenesis include endothelial 
dysfunction, accumulation of lipoproteins, platelet adhesion, monocyte adhesion and migration into 
the vessel wall, smooth muscle cell recruitment and proliferation, and excessive production of ECM.195, 
196 Clinical consequences of atherosclerosis include mechanical obstruction in the vascular lumen, 
plaque rupture with acute vascular thrombosis and aneurysm formation due to weakening of the 
underlying vessel wall.194  
Atherosclerosis is often measured by ultrasound assessments of total plaque area (TPA) and 
intima-media thickness (IMT) in the carotid artery. The prevalence of carotid atherosclerosis in the 
general adult population is approximately 25%,197 and the prevalence increases with increasing age.198 
Although both TPA and IMT are independent risk factors for stroke and MI, 198-201 a meta-analysis of 
population-based studies showed that the presence of carotid plaques had a higher diagnostic 
accuracy for the prediction of future arterial CVD, compared with IMT.202 Furthermore, studies have 
shown that there is no significant difference between the prevalence of atherosclerosis in the right 
and left carotid artery,203, 204 and that carotid atherosclerosis correlates well with the general extent of 
atherosclerotic disease in an individual.205, 206 Although the association between atherosclerosis and 
arterial CVD is well established, the association between atherosclerosis and VTE remains 
controversial.  
In a case-control study from 2003, Prandoni and colleagues found a higher frequency of carotid 
plaques in patients with unprovoked VTE (47%) compared with patients with provoked events (27%) 
and controls (32%). The multivariable-adjusted OR for carotid plaques in patients with unprovoked 
VTE, compared with patients with provoked events and controls, were 2.3 (95% CI 1.4-3.7) and 1.8 
27 
 
(95% CI 1.1-2.9), respectively.3 In the following years, the association between atherosclerosis and VTE 
was confirmed by other case-control studies, with 91-300 participants.  Unprovoked VTE was 
significantly associated with coronary artery calcium on CT angiography,207 increasing IMT208, 209 and 
presence of plaques208, 209 after adjusting for cardiovascular risk factors. Suggested mechanisms for the 
possible association between atherosclerosis and VTE are shared risk factors and common 
pathophysiological mechanisms, such as endothelial dysfunction, inflammation, platelet activation, 
and coagulation activation.207-209 
Prospective studies have not shown an association between subclinical atherosclerosis and 
VTE.4-6 In a study with nearly 16,000 participants aged 45-64 recruited from the general population, 
there was no association between atherosclerosis, as measured by IMT and TPA, and VTE in the 
adjusted models.5 In another cohort study, with participants above 65 years of age, any subclinical 
atherosclerosis was associated with a reduced risk of VTE (adjusted HR 0.60, 95% CI 0.39-0.90). This 
was mostly explained by an inverse association of high-risk carotid plaques and VTE.6 To ensure 
appropriate measurement and classification of atherosclerosis and to eliminate possible mediation of 
MI, Hald and colleagues calculated and compared risks of MI and VTE associated with atherosclerosis, 
and applied a cause-specific model. In a study of 6,300 participants aged 25-84 recruited from the 
general population, they found a strong association between carotid atherosclerosis and future MI, 
but not VTE.4 The follow-up time in the cohort studies ranged from 11.7 to 15.4 years.4-6 The 
association between the formation and progression of atherosclerosis and risk of VTE has not been 
investigated. 
The evident discrepancy in results between the case-control and cohort studies can possibly 
be explained by differences in study design. In the case-control studies, atherosclerosis was measured 
after the VTE event occurred. Thus, it is not possible to determine the temporal sequence between 
atherosclerosis and VTE (an inherent limitation of case-control studies). Furthermore, the case-control 
studies were prone to selection bias, especially because the control groups were small (48 cases and 
44 controls in the smallest study).208 In the cohort studies, measurements of atherosclerosis were 
performed before the outcome, and a temporal sequence could be established. However, 
atherosclerosis may develop over time and a true association between atherosclerosis and VTE may 







2. Aims of the thesis 
The aims of the thesis were: 
• To investigate the overall and time-dependent risk of VTE by ischemic stroke in a population-
based cohort with validated information on exposure, outcome and potential confounders 
(Paper I) 
 
• To investigate the association between the presence, formation, and progression of carotid 
atherosclerosis and VTE using a prospective cohort with repeated measurements, in 
participants recruited from the general population (Paper II) 
 
• To investigate whether the use of repeated measurements of atherosclerotic risk factors 
influenced the risk estimates for VTE and MI compared with baseline measurements only, in a 
prospective cohort recruited from the general population (Paper III) 
 
• To investigate if the association between a family history of myocardial (FHMI) infarction and 
VTE were explained by the presence of prothrombotic genotypes and to assess the combined 
effects of FHMI and prothrombotic genotypes on the risk of VTE in a case-cohort study 














3.1 Study population – The Tromsø Study and the HUNT Study 
The Tromsø study is a single-center population-based cohort study with repeated health 
surveys of the inhabitants of the municipality of Tromsø. It was initiated in 1974 to determine the 
causes of the high cardiovascular mortality in Norway and to develop interventions to prevent MIs and 
strokes.210 Seven surveys have been conducted and the study now includes a wide range of 
examinations and diseases. The surveys used for the papers in this thesis were conducted in 1994-
1995 (Tromsø 4), 2001-2002 (Tromsø 5) and 2007-2008 (Tromsø 6). To these surveys, the entire 
(Tromsø 4) or parts of the population (Tromsø 5 and 6) aged 25 years or older were invited to 
participate, and 27,158, 8,130 and 12,984 participants attended in Tromsø 4, 5 and 6, respectively. 
Attendances were high, ranging from 79% in Tromsø 5 to 66% in Tromsø 6. In the fourth survey, all 
inhabitants aged 55-74 years and a random 5-10% sample in the other age groups were invited to a 
second, more extensive examination. Subjects who attended the second visit in Tromsø 4, in addition 
to random samples within different age-groups of the fifth and sixth surveys, were eligible for the 
second visit of Tromsø 5 and Tromsø 6. In all papers, participants with a history of VTE before baseline 
were excluded. 
 The Nord-Trøndelag Health (HUNT) Study was primarily designed to determine the prevalence 
of hypertension, diabetes and undiagnosed tuberculosis, and to evaluate the quality of health care 
provided to these patients. The first survey was conducted in 1984-1986, and 74,599 participated 
(attendance of 88%). In 1995-1997, the second survey of the HUNT Study (HUNT 2) was conducted. 
The main objectives of this survey focused on important public health issues, such as cardiovascular 
disease, diabetes, obstructive lung disease, osteoporosis, and mental health. In HUNT 2, all individuals 
at the age of 20 and older living in Nord-Trøndelag County were invited, and 66,140 participated 
(71%).211 The third survey of the HUNT Study was completed in 2008, and the fourth survey started in 
2017. 
 Paper I and III in the thesis were based on information from Tromsø 4-6, and the participants 
were followed from enrollment in 1994-1995 until December 31, 2010. In Paper I, participants who 
developed ischemic stroke during the study period contributed with unexposed person-time from 
inclusion to the date of ischemic stroke, and then with exposed person-time from the date of ischemic 
stroke and onwards. Paper II includes participants attending one or more extensive examination in 
Tromsø 4-6, and participants were followed from the date of enrollment until December 31, 2012. 
Paper III included subjects enrolled in the fourth survey who attended or was supposed to attend the 
fifth and sixth survey. Subjects who were re-invited after Tromsø 4, but failed to attend one or more 
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visits were excluded from the follow-up, while subjects who moved or died were included and 
censored at the date of migration or death. Paper IV was based on information from Tromsø 4 and 
HUNT 2, and participants were followed from inclusion (1994-1995 in Tromsø 4 and 1995-1997 in 
HUNT 2) until December 31, 2008, in HUNT 2 and December 31, 2012, in Tromsø 4.  
 
3.2 Exposure assessment 
3.2.1 Ischemic stroke 
Ischemic stroke was defined according to the WHO definition (i.e. an acute disturbance of focal 
or global cerebral function with symptoms lasting ≥ 24 hours or leading to death of presumed vascular 
origin),212 when CT or MRI scans or autopsy had ruled out brain hemorrhage. The national 11-digit 
identification number allowed linkage to national and local diagnosis registries. Possible cases of 
incident ischemic stroke were identified by searching hospital discharge diagnosis registry at the 
University Hospital of North Norway (UNN) and the National Causes of Death Registry at Statistics 
Norway, which covers participants living in Norway at the time of death regardless of the place of 
death. The 9th revision of the International Classification of Diseases (ICD-9) codes 340 to 438 was used 
from 1994 to 1998, and the 10th revision of ICD codes (ICD-10) I60 to I69 were used thereafter. Manual 
text searches were used until 2001 when medical records became digital, and electronic text searches 
were used thereafter. To ensure case completeness, manual and/or electronic text searches were 
performed in all participants with ICD-9 codes 410-414, 427 and 789-799 and ICD-10 codes I20-I25, 
I47.1, I48, R96, R98, and R99. Medical records, autopsy records and death certificates were retrieved 
for case validation by an independent end-point committee. 
 
3.2.2 Cardiovascular risk factors 
Information on cardiovascular risk factors was collected by physical examination, non-fasting 
blood sampling, and self-administered questionnaires, and the collection of data was repeated at each 
survey. Height and weight were measured with participants wearing light clothing and no shoes. BMI 
was calculated by the weight in kilograms (kg) divided by height in meters (m) squared (kg/m2). 
Overweight (BMI 25-29.9 k/m2) and obesity (BMI ≥ 30 kg/m2) was defined according to the WHO.116 
Blood pressure was measured three times with an automatic device (Dinamap Vital Signs Monitor in 
Tromsø 4 and Dinamap 845XT [Critikon] in HUNT 2) in a sitting position after two minutes of rest. The 
average of the two last readings was used in the analyses. Subjects were defined as hypertensive if 
they had systolic blood pressure ≥ 140, or diastolic blood pressure ≥ 90 or if they reported current use 
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of antihypertensive medication. Total cholesterol, triglycerides, and HDL were measured in blood 
samples collected from an antecubital vein. Detailed information on handling and analyses of the blood 
samples have been published elsewhere.17, 211 Hypercholesterolemia was defined as total cholesterol 
≥ 6.5 mmol/L or use of lipid-lowering drugs. Low HDL cholesterol was defined as ≤ 1.03 mmol/L in men 
and ≤ 1.30 mmol/L in women, according to the National Cholesterol Education Program - Adult 
Treatment Panel III guidelines.213 The questionnaires were used to obtain information on current 
smoking (yes/no), diabetes mellitus, physical activity, education and medication use, including the use 
of antihypertensive medication and lipid-lowering drugs.  
 
3.2.3 Carotid atherosclerosis 
The ultrasound examination was a part of the second and extensive examination at each 
survey. High-resolution B-mode and color Doppler ultrasonography were used to scan the right carotid 
artery longitudinally from the level of the clavicle, through the carotid bulb (bifurcation segment) and 
the proximal internal carotid segment (ICA) as far downstream as possible. An Acuson Xp10 128 ART 
ultrasound scanner equipped with a 7.5-MHz linear-array transducer was used in Tromsø 4 and 5, and 
a GE Vivid 7 with a linear 12-MHz transducer was used in Tromsø 6. Still images were reported for each 
plaque and digitized using the Matrox Meteor II frame grabber card and Matrox Intellicam (Matrox 
Imaging, Montreal, QC, Canada). With the use of Adobe Photoshop 7.0, measurements of plaque area 
were made by outlining the perimeter of the plaque, and the plaque area was calculated as pixel 
values. To ensure equal and standardized examination techniques and measurement procedures, all 
sonographers completed a two-month pre-study training protocol. In addition, subjects were 
randomly distributed among the different sonographers, who were blinded to data from the 
questionnaires and blood samples.214 Inter-observer reproducibility of the ultrasound examinations 
was found to be good.198 
A plaque was defined as a localized protrusion of the vessel wall into the lumen of at least 50% 
compared with the adjacent IMT. In each subject, a maximum of six plaques were registered in the 
near and far walls of the distal part of the common carotid artery (CCA), bifurcation, and ICA, 
respectively. TPA was calculated as the sum of all plaques. IMT was defined as the average of the mean 
IMT values of the near and far wall of the CCA and far wall of the bifurcation. To minimize variability in 
IMT during the cardiac cycle, the image capturing was standardized by recording images at the top of 
the R wave in an electrocardiographic (ECG) signal. Plaque initiation was defined as development of 
new plaques at follow-up in vessels without plaques at the previous examination, and plaque 
32 
 
progression as the difference in TPA between two measurements. Participants with negative 
progression were included in the no progression group.198, 215 
 
3.2.4 Family history of myocardial infarction 
To identify FHMI, subjects were asked to report whether their mother, father, sister, brother, 
child or none in the family had a history of MI before the age of 60 years in the self-administered 
questionnaires. A positive FHMI was regarded as ≥ 1 first-degree relative with a history of MI before 
the age of 60 years. Parental FHMI was regarded as ≥ 1 parent with a history of MI before the age of 
60 years. The questionnaire picks out 80% of the confirmed MI-positive family histories.216, 217 
 
3.2.5 Prothrombotic genotypes 
  The following SNPs were genotyped and used in Paper IV: rs8176719 in ABO (non-O blood 
type), rs6025 in F5 (FVL), rs1799963 in F2 (prothrombin G20210A), rs2066865 in FGG and rs2036914 
in F11. In the Tromsø Study, rs8176719 (ABO), rs6025 (F5), rs1799963 (F2) and rs2036914 (F11) were 
genotyped with the Sequenom platform, and rs2066865 (FGG) with the TaqMan platform, as 
previously described.218 The HUNT Study performed genotyping using the Illumina HumanCore Exome 
array. 
Participants were considered carriers of the prothrombotic risk gene when one or two risk 
alleles were present. We did not differentiate in hetero- and homozygotes due to few homozygote 
study participants. The only genetic variant with a minor allele associated with a reduced risk of VTE 
was the rs2036914 in F11, and in this case, we considered the common allele as the risk allele.219 For 
rs8176719 (ABO), zero risk alleles were classified as O blood type, whereas one or two risk alleles were 
classified as non-O blood type. The 5-SNP score conceived by de Haan and colleagues was created by 
summarizing the number of risk alleles from the five sequenced SNPs.106 
 
3.3 Outcome assessment 
3.3.1 Venous thromboembolism 
In the Tromsø Study, all incident VTE events were identified by searching the hospital discharge 
diagnosis registry, the autopsy registry and the radiology procedure registry at UNN. UNN is the only 
hospital in the Tromsø region, and provides all relevant radiological procedures and hospital care. The 
discharge diagnosis codes used from 1994-1998 were 325, 415.1, 451-453, 671.3, 671.4 and 671.9 
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from ICD-9. From 1999 to 2012, the relevant codes from ICD-10 were I26, I80-I82, I67.6, O22.3, O22.5, 
O87.1, and O87.3. Manual text searches were used until 2001 when medical records became digital, 
and electronic text searches were used thereafter. In the HUNT Study, incident VTE events were 
identified by searching the hospital discharge diagnosis registry and the radiology procedure registry 
at the two local hospitals in the county (Levanger Hospital and Namsos Hospital) and by searching the 
discharge diagnosis registry at the tertiary-care center of the region, St. Olav’s Hospital in Trondheim 
(Sør-Trøndelag County). The discharge diagnosis codes used were ICD-9 codes 415, 451-453, 325, 
362.3, 433, 557.0, 634-638 (with decimals 6 and 7), 639.6, 639.8, 639.9, 671, 673, 674 and 997.2, and 
ICD-10 codes I26, I80-I82, I63.6, I67.6, K55, H34.8, O08, O22, O87 and O88. 
The medical record for each potential case of VTE was reviewed by trained personnel. In the 
Tromsø Study, a VTE was verified and recorded when clinical signs and symptoms of DVT or PE were 
combined with objective confirmatory tests (i.e. compression ultrasound, venography, spiral 
computed tomography [CT], perfusion-ventilation scan, pulmonary angiography, and autopsy), and 
resulted in a diagnosis made by a physician that required anticoagulant treatment (i.e. low-molecular-
weight heparin [LMWH], vitamin K antagonists or similar agents, thrombolytic therapy or vascular 
surgery). DVTs were recorded in the upper and lower extremities, including the inferior vena cava, and 
at unusual sites (i.e. the mesenteric veins, portal vein and in the venous sinuses). VTE cases from the 
autopsy registry were recorded when the death certificate indicated VTE as the cause of death or as a 
significant condition contributing to death. In the HUNT study, a VTE diagnosis required positive 
objective confirmatory tests (ultrasonography, venography, CT, perfusion ventilation scan or 
echocardiogram).  
 VTEs were classified as DVT or PE, and if DVT and PE occurred simultaneously it was recorded 
as a PE. Furthermore, the VTEs were classified as unprovoked or provoked, depending on the presence 
of provoking factors at the time of diagnosis. In the Tromsø Study, provoking factors included surgery, 
trauma or acute medical conditions (i.e. MI, ischemic stroke or major infections) within the last three 
months, active cancer, immobilization (i.e. bed rest for more than three days, wheelchair use or long-
distance travel exceeding four hours within the last 14 days prior to the event) or any other factors 
described by a physician in the medical records (e.g. intravascular catheter). In the HUNT Study, 
provoking factors were active cancer at the event or within six months after the event, trauma, surgery 
or marked immobilization (paresis, paralysis, prolonged bedrest due to an acute medical illness or 
travel for more than eight hours) within the last three months, pregnancy or puerperium at the time 
of the event and oral contraceptives used at the time of the event or up to one month prior to the 




3.3.2 Myocardial infarction 
Incident MI events were validated according to modified WHO MONICA/MORGAM criteria, 
including clinical signs and symptoms, findings in electrocardiograms, values of cardiac biomarkers and 
autopsy reports when applicable.220 We included all events classified as definite, probable and possible 
MI (Table 2).221 The unique nation 11-digit identification number allowed linkage to national and local 
diagnosis registries. Possible cases of incident MI were identified by searching the hospital discharge 
diagnosis registry at the UNN by searching for ICD-9 codes 410-414, 430-438 and 798-799 in the period 
1994-1998, and ICD-10 codes I20-I25, I60-I69, and R96, R98 and R99 thereafter. Manual text searches 
were used until 2001 when medical records became digital, and electronic text searches were used 
thereafter. In addition, the National Causes of Death Registry at Statistics Norway was searched, 
allowing identification of fatal MI events that occurred as out-of-hospital deaths, including deaths that 
occurred outside the municipality of Tromsø. Medical records, autopsy records and death certificates 






Table 2. Classification algorithm for myocardial infarction (MI) in the Tromsø Study. 
Definite MI Defined by one of the following conditions: 
• Typical, atypical or inadequately described symptoms and a definite new 
infarction in ECG recordings 
• Typical symptoms and significantly higher myocardial enzyme and/or 
troponin levels 
• Atypical or inadequately described symptoms and significantly higher 
myocardial enzyme and/or troponin levels and a probable new infarction on 
ECG recordings 
• Postmortem evidence of recent MI or thrombosis 
Probable MI Defined by one of the following conditions:  
• Typical, atypical or inadequately described symptoms and a probable new 
infarction in ECG recordings and moderately increased myocardial enzyme 
and/or troponin levels 
• Typical symptoms and moderately higher myocardial enzyme and/or 
troponin levels 
• Atypical or inadequately described symptoms and significantly higher 
myocardial enzyme and/or troponin levels 
• Atypical or inadequately described symptoms and moderately higher 
myocardial enzyme and/or troponin levels and probable new infarction on 
ECG recordings 
• Sudden death with no evidence of non-coronary cause of death 
Possible MI An event that can be dated and for which secondary data of typical history in 
combination with ECG findings and/or echocardiography and/or autopsy are 
consistent with MI but for which no primary data source is available 
Unstable 
angina 
Angina at rest of minimal exertion and ST-depression or negative T-wave in ECG 
Unclassifiable Increase in troponins or enzymes in relation to cardiac revascularization 
procedures (percutaneous coronary intervention or coronary artery bypass 
grafting) or otherwise unclassifiable 
Silent MI Defined as one of the following, in combination with the absence of clinical 
symptoms: 
• New diagnostic Q-wave in incidental ECG 
• Evidence of MI on echocardiography and/or multigated acquisition scan 
• Evidence of MI at autopsy 
No MI The conclusion after the validation procedure is that the event does not fulfill 
the criteria for an acute coronary event 
(Adapted from Skjelbakken et al, J Am Heart Assoc, 2014) 
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4. Main results 
4.1 Paper I 
Ischemic stroke and risk of venous thromboembolism in the general population: the Tromsø Study 
Even though clinical data support a relation between stroke and VTE, the strength and time 
dependence of the association remains to be settled at the population level. We therefore aimed to 
investigate the association between ischemic stroke and VTE in a prospective population-based cohort. 
Participants (n=30,002) were recruited from 3 surveys of the Tromsø Study (conducted in 1994-1995, 
2001-2002 and 2007-2008) and followed to December 2010. All incident events of ischemic stroke and 
VTE during follow-up were recorded. Cox regression models with age as time-scale and ischemic stroke 
as a time-dependent variable were used to calculate HR of VTE, adjusted for cardiovascular risk factors. 
During a median follow-up time of 15.7 years, 1,360 participants developed ischemic stroke and 722 
had an incident VTE event. 57 participants experienced an ischemic stroke and a subsequent VTE 
event. The risk of VTE was highest the first month (HR 19.7, 95% CI 10.1-38.5) and from one to three 
months after the ischemic stroke (HR 10.6, 95% CI 5.0-22.5), but declined rapidly thereafter. The risk 
estimates were approximately the same for DVT and PE with HRs of 19.1 (95% CI 7.8-38.5) and 20.2 
(95% CI 7.4-55.1), respectively. Ischemic stroke was associated with a higher risk of provoked (HR 22.6, 
95% CI 12.5-40.9) than unprovoked VTE (HR 7.4, 95% CI 2.7-20.1) the first three months. In conclusion, 
the risk of VTE was increased during the first three months after an ischemic stroke. The particularly 
high risk of provoked VTE suggests that additional predisposing factors related to the stroke itself, such 












4.1.1 Erratum – Paper I 
In November 2016, we published the paper Ischemic stroke and risk of venous 
thromboembolism in the general population. The Tromsø Study in the Journal of American Heart 
Association.  
Recently, we were made aware that figure 2 in the paper was incorrect. In the figure, the values 
on the y-axis range from 1 to 100, while the values were supposed to range from 1 to 10. As a 
consequence, the cumulative incidence displayed in the figure is higher than it should be. Except for 
the corrected y-axis, the new figure is identical to the published figure, and the implication of the 
results remains the same.  
The text describing the figure and the cumulative incidence is also incorrect, and a higher 
cumulative incidence than actually observed is reported. The correct text should be: The cumulative 
incidences of VTE in subjects without and with ischemic stroke are shown in Figure 2. There was a 
notable increase in the cumulative incidence of VTE during the initial 3 months following an incident 
stroke as displayed by the substantially steeper slope in the incidence curve for subjects with ischemic 
stroke compared to those without ischemic stroke. The cumulative incidence of VTE was 1.5% during 
the first 3 months in subjects with ischemic stroke, compared with 0.02% in the general population 
during the same time period. The incidence curves for VTE remained essentially parallel in the period 






4.2 Paper II 
Repeated measurements of carotid atherosclerosis and future risk of venous thromboembolism: the 
Tromsø Study 
Whether a relationship between atherosclerosis and subsequent VTE exists is controversial. Previous 
case-control studies have reported an association between carotid plaques and VTE, whereas cohort 
studies have not shown any association between carotid atherosclerosis and subsequent VTE. Because 
atherosclerosis may develop over time, regression dilution bias can lead to underestimation of a true 
association in cohort studies. We aimed to investigate the association between carotid atherosclerosis 
and VTE by using repeated measurements of IMT and TPA in participants recruited from the general 
population. Participants were recruited from the fourth (1994-1995), fifth (2001-2002) and sixth (2007-
2008) surveys of the Tromsø Study. In total, 10,426 participants were included, for whom 
measurements of carotid IMT and TPA and potential confounders were updated at each available 
survey. Time-varying Cox regression models were used to calculate HR of VTE across levels of IMT and 
TPA, adjusted for age, sex and BMI. During a median follow-up of 10.8 years, there were 368 incident 
VTE events. Participants with increasing IMT were older and had a less favorable cardiovascular risk 
profile. There was no association between TPA and risk of VTE, and increasing IMT was not associated 
with increased risk of VTE (HR 0.96, 95% CI 0.86-1.07). Neither plaque formation nor plaque 
progression was associated with VTE (HRs of 1.00, 95% CI 0.98-1.02 and 0.96, 95% CI 0.84-1.11, 
respectively). Additional adjustments for traditional cardiovascular risk factors had a negligible effect 
on the risk estimates. In conclusion, our study shows that carotid IMT and TPA were not associated 
with an increased risk of VTE using a time-varying analysis with repeated measurements. Furthermore, 
there was no association between plaque formation of plaque progression and subsequent VTE. The 
findings suggest that atherosclerosis is not an intermediate for the association between arterial 










4.3 Paper III 
Atherosclerotic risk factors and risk of myocardial infarction and venous thromboembolism; time-
fixed versus time-varying analyses. The Tromsø Study 
Single measurements of modifiable risk factors may underestimate associations with outcomes in 
cohorts due to regression dilution bias, especially if follow-up is long. We aimed to compare risk 
estimates of MI and VTE by atherosclerotic risk factors during long follow-up using time-fixed and time-
varying analysis. The study included 5,970 subjects enrolled in the fourth survey of the Tromsø Study 
(1994-1995). Atherosclerotic risk factors, including blood pressure, lipid levels, BMI, diabetes, and 
smoking status, were measured at baseline, and subjects still alive at the fifth (2001-2002, n=5,179) 
and sixth (2007-2008, n=4,391) survey were re-measured. Time-fixed and time-varying Cox regression 
models were used to estimate HR for MI and VTE adjusted for age and sex. Until December 2012, there 
were 714 and 214 incident MI and VTE events, respectively. During a median follow-up time of 15.7 
years, we found that variations in BMI, blood pressure and lipid levels were small. For these risk factors, 
risk estimates of MI and VTE were similar in the time-fixed and time-varying analyses. For MI, variables 
that changed considerably over time yielded the greatest changes in risk estimates. For example, HR 
for smoking was 1.80 (95% CI 1.55-2.10) in the time-fixed and 2.08 (95% CI 1.78-2.42) in the time-
varying analysis. For VTE, there was a significant association with BMI and hypertension in both the 
time-fixed and the time-varying model. However, the association with hypertension disappeared when 
adjusting for BMI in addition to age and sex. For BMI, the risk of VTE was slightly lower in the time-
varying analysis compared with time-fixed analysis. Our findings suggest that for MI and VTE, risk 
estimates based on baseline and repeated measurements correspond well. Furthermore, 
misclassification is a problem only in situations where the association is between exposure and 
outcome is strong and the exposure varies greatly during follow-up. Of the traditional atherosclerotic 
risk factors, only BMI was associated with VTE, suggesting that underestimation of risks by regression 








4.4 Paper IV 
Impact of prothrombotic genotypes on the association between family history of myocardial 
infarction and venous thromboembolism 
A family history of myocardial infarction (FHMI) increases the risk of venous thromboembolism (VTE). 
We aimed to investigate the effect of prothrombotic genotypes on the association between FHMI and 
VTE in a case-cohort recruited from a general population. In a case-cohort analysis, cases with a first 
VTE (n=1,493) and a sub-cohort (n=13,072) were sampled from the Tromsø study (1994-95) and the 
Nord-Trøndelag Health (HUNT) Study (1995-1997). DNA-samples obtained at baseline were genotyped 
for rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG) and rs2036914 (F11). Participants 
not officially registered as inhabitants in Tromsø or Nord-Trøndelag at baseline (n=3) were excluded. 
Furthermore, we excluded participants with missing information on SNP variables (n=175), FHMI 
(n=2,769) and BMI (n=52). Cox regression models were used to estimate hazard ratios (HRs) for VTE 
and all analyses were adjusted for age, sex, and BMI. There were 1,169 incident VTEs during a median 
follow-up time of 12.3 years. FHMI was associated with a 1.3-fold increased risk of VTE (HR 1.32, 95% 
CI 1.16-1.50) and 1.5-fold increased risk of unprovoked VTE (HR 1.47, 95% CI 1.22-1.78). The risk of VTE 
by FHMI did not alter in analysis adjusted for the five genotypes. The combination of FHMI and the 
different prothrombotic genotypes did not result in an excess VTE risk. For instance, having both FHMI 
and non-O blood type (rs8176719) was associated with a 1.8-fold increased risk of VTE (HR 1.78, 95% 
CI 1.49-2.13), which approximated the sum of having only FHMI (HR 1.35, 95% CI 1.07-1.71) or non-O 
blood type (HR 1.38, 95% CI 1.19-1.59). Thus, FHMI and the prothrombotic genotypes had an additive 
effect (i.e. no biological interaction) on the risk of VTE. In conclusion, our findings suggest that the 
association between FHMI and VTE is not explained by rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), 
rs2066865 (FGG) and rs2036914 (F11). FHMI combined with prothrombotic genotypes had an additive 








5. General discussion 
5.1 Methodological considerations 
5.1.1 Study design 
The papers in this thesis are based on data from the Tromsø Study and the HUNT Study, two 
prospective population-based cohort studies.  
In Paper I-III, we used a cohort study design. In a cohort study, a predefined population is 
followed from the date of inclusion in the study until an outcome of interest occurs, or until migration, 
death or end of study period. An advantage with cohort studies is that it is possible to relate one or 
more characteristics to future outcomes, and thus study the natural history of risk factors and diseases 
in individuals.222 Temporality is, among others, one of the criteria needed to provide epidemiologic 
evidence for causality.223 Other criteria for determining a causal relationship are strength of the 
association, consistency with other studies, a plausible mechanism between cause and effect and 
biological gradient (dose-response relationship).223 Thus, results from one cohort study is not enough 
to conclude on causality. Although a randomized controlled trial (RCT) would be the best study design 
to determine causality, it requires large amounts of resources, carries considerable ethical 
considerations and it may be impossible to carry out. For instance, it would be unethical and impossible 
to inflict carotid atherosclerosis on people in order to study the association between atherosclerosis 
and VTE.  
Another advantage of the cohort study design, as compared with other observational study 
designs, is that several exposures and outcomes can be investigated simultaneously. The nature of the 
Tromsø Study allowed us to investigate the association between risk factors and two different 
outcomes (MI and VTE). Furthermore, if cohort studies are based on a defined and well-characterized 
population, the incidence rates can be extrapolated beyond the study group to similar populations 
elsewhere (discussed in section 5.1.7).222 This is in contrast to case-control studies and the majority of 
RCTs with highly selected study participants.  
Some limitations of the cohort study design merit consideration. First, cohort studies are 
inefficient for studying incidence and associations of rare outcomes because it would require large 
populations and/or many years of follow-up, and thus be very resource-demanding. However, the 
outcomes used in the papers of the present thesis (MI and VTE) are common in the general population. 
Second, change in exposure during follow-up can lead to regression dilution bias and underestimation 
of associations. Third, cohort studies, as well as other types of observational study designs, are prone 
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to bias and confounding. Advantages and limitations of the cohort study design will be discussed in the 
following sections.  
In Paper IV, we used a case-cohort study 
design with subjects recruited from Tromsø 4 and 
HUNT 2. A case-cohort study is a variant of a cohort 
study, in which participants (cases and a sub-cohort) 
are recruited from a parent cohort after baseline. 
Case-cohort studies are often used when large cohorts 
are needed to observe enough cases, but it is not 
feasible to collect data on covariates for the whole 
cohort. As genotyping is time-consuming and 
expensive, the case-cohort design is optimal for 
investigating the aims in Paper IV.  
Because assessments of risk factors were done 
at baseline, before the outcome occurred, there is a temporal sequence of exposure and outcome in 
the case-cohort studies. As with cohort studies, incidences, absolute risks, and relative risks can be 
calculated. The sub-cohort is reflecting the source population, and every person in the cohort has an 
equal chance of being included in the study as a control, regardless of how much time that person 
contributed with and whether the person developed the disease.224 Thus, with appropriate sampling 
and analyses, the risk estimates in a case-cohort study are similar to risk estimates derived from the 
full cohort.225 For Paper IV, all incident cases of VTE (n=1,493) and a randomly selected sub-cohort 
(n=13,072) from Tromsø 4 and HUNT 2 were included in the study (Figure 4). As every person had an 
equal chance of being included in the sub-cohort, the sub-cohort included 217 cases. After exclusion 
of participants not officially registered as inhabitants in Tromsø or Nord-Trøndelag, and participants 
with missing values for at least one of the risk alleles studied, FHMI or BMI, the study consisted of 
11,618 participants with 1,169 VTE events. Because of the size of the sub-cohort, we did not make 
adjustments to the partial likelihood in the Cox regression analyses.226  
 
5.1.2 Bias 
Bias is the term for systematic errors in epidemiological research that results in incorrect 
estimates of the true association between an exposure and an outcome. Depending on the types of 
systematic errors, bias can lead to overestimation or underestimation of risk estimates. There are 
several types of biases, and they can be classified as either selection bias or information bias.222  




Selection bias is a result of systematic errors in the recruitment of participants, and occur when 
individuals have different probabilities of inclusion in the study sample according to relevant study 
characteristics, i.e. the exposure and outcome of interest.227 This type of bias is less likely to occur in 
cohort studies compared to case-control studies, because participants, exposed or unexposed, are 
recruited before the outcome develops. Nevertheless, cohort studies are prone to a type of selection 
bias called non-response bias (or participation bias). Non-response bias is introduced if participation 
rates differ between study participants with certain traits that affect the outcome (i.e. the study 
participants are systematically different from the target population).228, 229 In general, participation in 
epidemiological studies have declined over the past years, and attendees are more likely to be female, 
have higher socioeconomic status, higher education, and be married.228 In accordance to this, 
participation in the Tromsø Study have declined from around 83% in Tromsø 1-3 to 77% in Tromsø 4, 
79% in Tromsø 5 and 66% in Tromsø 6, and non-attendees tended to be younger, were more often 
men and unmarried. In both the Tromsø Study and the HUNT Study, people < 40 years of age and > 80 
years of age had lowest attendance.210, 211 After HUNT 2 was completed, a non-participation study was 
conducted. A random sample of non-participants was contacted by telephone or letter to investigate 
the reasons for non-attendance. In the younger age groups, the main reasons to not participate were 
lack of time or having moved out of the county. In the older age-groups, many reported to have regular 
follow-up by a general practitioner or at the hospital and therefore did not need to attend a health 
survey. Approximately 10% could not attend because they were immobilized due to disease.211 
Reduced attendance in population-based studies preclude generalizability to whole populations, and 
results regarding the youngest and oldest populations must thus be interpreted with caution. 
Furthermore, there is a strong relationship between socioeconomic status and MI,179 and low 
attendance among those with low socioeconomic status may have affected associations between 
cardiovascular risk factors and MI. However, non-response bias is of greater concern when estimating 
absolute risks (compared with relative risks), and most studies have found little evidence of substantial 
bias as a result of non-participation.222, 228 Nonetheless, it is important to maintain a high degree of 
participation, and the challenge for future surveys of the Tromsø Study will be to develop methods to 
increase recruitment and feasibility to optimize participation.  
Another type of selection bias in cohort studies is bias due to differential loss to follow-up. This 
type of bias would occur when the different exposure groups have a different probability of completing 
the study and is always of concern in cohort studies.230 In survival analysis, subjects are censored when 
they are lost to follow-up, for example, due to migration or death, because it is unknown if the 
outcome occurs in that person or not. An assumption of censored survival time is that participants who 
remain in the study have the same risk of the outcome as those who are no longer under follow-up 
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(called non-informative or independent censoring). In all papers in the present thesis, participants 
were censored when they moved from the municipality of Tromsø or when they died. As there is no 
reason to suspect that participants that moved from Tromsø had a different risk of MI or VTE than 
those who stayed, simple censoring at the date of migration is adequate. Conversely, death prevents 
the outcome of interest to occur, and the censoring becomes informative. This situation, in which 
death is a competing event, is called competing risk by death and is of special concern when 
investigating older populations231 and exposures related to high mortality, such as cancer.232 The 
absolute risk and cumulative incidence of an event are dependent on the rate of the event and the 
mortality rate. Hence, competing risk by death must be taken into account when dealing with absolute 
risks and cumulative incidences in prognostic research.232, 233 However, when investigating causality 
between an exposure and an outcome (etiological research), the exposed and unexposed individuals 
alive and actually at risk of developing the event of interest are compared. Censored participants 
contribute with exposed or unexposed person-time before the censoring event, and do not affect the 
hazard ratio after being censored.233 As the papers included in the present thesis investigated 
etiological associations between risk factors (i.e. stroke, atherosclerosis, cardiovascular risk factors, 
and FHMI) and VTE or MI, competing risk of death was not taken into account. 
In Paper III, we included participants who attended all three surveys, or was supposed to 
attend all three surveys, but died or moved during follow-up. This was to avoid selective inclusion of 
participants who survived the entire study period as these would more likely be healthier than those 
who died. However, we had to exclude participants without repeated measurements to investigate 
our aim, and we cannot rule out that those who were excluded differed from those who were included. 
Although the main aim of the study was to compare different methods, we cannot be certain that the 
selection did not affect the estimates.  
Systematic errors in a study’s data collection may lead to information bias. Misclassification 
bias is a type of information bias which occurs if included participants are incorrectly placed in different 
exposure or outcome categories. There are two types of misclassification: differential misclassification 
and non-differential misclassification.224 Differential misclassification occurs when the probability of 
misclassification differs with regards to exposure or outcome status, whereas non-differential 
misclassification occurs when all participants have the same probability of misclassification. As perfect 
tools to gather information rarely exists, most studies must assume a certain degree of 
misclassification.230 Differential misclassification can lead to both over- and underestimation of the 
true association, whereas non-differential misclassification consistently results in an underestimation 
of the true association. Consequently, non-differential misclassification is generally more “accepted” 
than differential misclassification.227 In cohort studies, differential outcome misclassification can occur 
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if exposure status affects the probability of getting diagnosed with a disease. To avoid differential 
outcome misclassification bias in our studies, the end-point committee was blinded to the participants’ 
baseline risk. 
Several of the variables used in our studies are self-reported through questionnaires (e.g. 
smoking, physical activity, and diabetes) and are potentially prone to misclassification. For example, 
self-reported information on smoking have shown to yield reliable estimates of true the smoking 
prevalence,234 whereas the reliability and validity of self-reported physical activity are worse.235 
Although self-reported diabetes have been shown to be reliable,236 the prevalence of self-reported 
diabetes in the Tromsø study is lower than expected. In 2016, WHO estimated that the prevalence of 
diabetes in Norway was 6.6%,237 however, the prevalence of self-reported diabetes ranged from 2% in 
Tromsø 4 (1994-1995) to 5% in Tromsø 6 (2007-2008). The increasing prevalence is likely a result of a 
true increase in the prevalence of diabetes during the last decades and increasing awareness of 
diabetes in the population and among doctors. The discrepancy between the self-reported prevalence 
and true prevalence of diabetes is probably due to underdiagnosing of type 2 diabetes due to few 
symptoms. As awareness and testing of diabetes has increased during the last decades, the 
discrepancy between self-reported and true prevalence has decreased. Nevertheless, the degree of 
misclassification related to self-reported variables will be similar in those who experience the outcome 
and those who do not (i.e. non-differential) because baseline measurements are collected before the 
outcome occurs. This will lead to an underestimation of true results.  
Validation of the FHMI variable in the Tromsø Study showed high concurrence between 
reported and confirmed diagnoses,216 and another study validating self-reported FHMI found high 
specificity (97%) and lower sensitivity (68%) of a positive FHMI.238 Furthermore, measurement errors 
in the physical examinations may occur, for instance, if blood pressure was measured with a defect 
sphygmomanometer. However, as participants answered the questionnaires and underwent the 
physical examinations at the start of the study, and were thus unaware of future disease, the 
misclassification of the self-reported variables are non-differential. To minimize non-differential 
misclassification, examinations were standardized, e.g. blood pressure was measured three times and 
the average of the last two was used, and height was measured without shoes.  
Medical surveillance bias can occur if an exposure leads to closer surveillance and an increased 
probability of detection of an outcome.239 This is of special concern if the outcome of interest is 
subclinical and exposed individuals are more likely to be examined. For instance, patients with 
suspected PE are examined with CT, which may also detect (subclinical) pulmonary diseases. The 
pulmonary diseases may be just as prevalent in the unexposed, and the apparent association is caused 
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by increased surveillance of patients with PE. Medical surveillance bias may be of concern in Paper I, 
as it is plausible that stroke patients were more closely monitored for VTE and had a higher probability 
of getting a VTE diagnosis compared with participants without stroke. Although VTE was thoroughly 
validated and the diagnosis required signs and symptoms of VTE and objective confirmatory tests, it is 
likely that stroke patients with signs of VTE were more likely to undergo diagnostic tests for VTE 
compared with unexposed participants with similar signs. This may have overestimated the incidence 
rate and HR among the exposed. 
 
5.1.3 Modifiable risk factors and regression dilution bias 
Regression dilution bias is a potential limitation of a cohort study with a single measurement. 
Regression dilution bias is caused by random (non-differential) measurement errors, temporary 
fluctuations and true changes in variables over time, and results in an underestimation of the true 
association between exposure and outcome.230, 240 In agreement with this, previous studies have 
shown that the use of single baseline measurements of cardiovascular risk factors greatly 
underestimated the true association with coronary heart disease.241, 242 Methods to reduce random 
measurement errors during study conduction include using standardized measurement approaches 
and using the average of several measurements. In study analyses, regression dilution bias can be 
addressed by performing time-varying analyses if repeated measurements are available for the entire 
or parts of the cohort.182, 183 
The main aim of Paper III was to investigate whether the use of repeated measurements of 
cardiovascular risk factors influenced the risk estimates for VTE and MI compared with baseline 
measurements only, and if the lack of association between cardiovascular risk factors and VTE in 
previous cohorts could be explained by regression dilution bias. We concluded that risk estimates for 
MI and VTE based on baseline measurements and time-fixed analyses corresponded well with risk 
estimates based on repeated measurements and time-varying analyses. Only BMI was associated with 
VTE, indicating that possible underestimation of risks due to regression dilution bias did not explain 
the lack of association between cardiovascular risk factors and VTE. The risk estimates based on a single 
baseline measurement were generally reliable, and dilution of risk estimates was a problem in 
situations where the association between exposure and outcome is strong, and when the exposure 
status varies greatly during follow-up. 
In Paper I and II, information on possible confounders was updated at each survey for those 
who participated in more than one survey. Repeated measurements of carotid atherosclerosis also 
allowed us to assess if the initiation or progression of atherosclerosis increased the risk of VTE. As we 
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did not have updated measurements for any of the participants of the HUNT study, we used single 
baseline measurements and traditional time-fixed analyses for Paper IV. Furthermore, genotypes are 
not modifiable, and, as Paper III suggested, risk estimates of VTE based on single measurements and 
repeated measurements corresponded well for BMI.  
 
5.1.4 Confounding and mediation 
Confounding is often considered as one of the main categories of bias. The concept of 
confounding refers to a situation where the association between an exposure and an outcome can be 
attributed to the influence of a third, known or unknown, variable (Figure 5).227 A variable is a 
confounder if (i) it is an independent risk factor for the outcome, either causal or a surrogate for a 
causal factor, (ii) it is associated with the exposure, and (iii) is not an intermediate variable between 
the exposure and the outcome.224, 227, 243 When investigating the presumably causal association 
between a risk factor a and an outcome c, an additional variable b would be a confounder if it is an 
independent risk factor for c, associated with a and not an intermediate between a and c. For instance, 
age is an obvious confounder for the association between grey hair and mortality. Confounders are of 
special concern in etiological research, in which causal relationships are investigated.244 Mediation 
closely resembles confounding, but the criteria for mediation is that the mediator is a presumed causal 
effect of the risk factor of interest (i.e. a causes b, see Figure 5).243 Adjusting for a mediator in 
regression analysis will show the direct effect of a risk factor on an outcome, by removing the indirect 
effect caused by the mediator. However, the mediator does not act as a confounder for the association, 
it is the reason why the risk factor and the outcome are associated, and exposure a is still causally 
related to outcome c. Mathematically, there is no difference between a confounder and a mediator, 
and it is not always clear whether a variable is a confounder or a mediator.  If an association between 
a risk factor and an outcome diminishes after adjusting for a variable, we cannot conclude that the 
Figure 5. The concept of confounding and mediation. 
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unadjusted association was an artifact due to confounding. The variable could have been a mediator 
in the causal pathway between the risk factor and an outcome, and adjusting for the variable would 
underestimate the true association between the risk factor and the outcome.243 Mediation analyses 
can be performed to investigate to what extent an association is mediated through a third variable.245 
Although it might be difficult, it is important to use non-statistical arguments to decide whether the 
third variable is a confounder or a mediator.  
In RCTs, participants are randomly assigned to treatment groups, balancing potential 
confounding factors between the groups. Observational studies do not randomize the exposure, and 
failing to adjust for confounding in the analyses can result in associations that are overestimated, 
underestimated or even reversed, compared with the true association.227 Strategies to minimize 
confounding include, among others, stratified analyses in which different strata of an exposure are 
analyzed separately, and regression modeling with confounders included in a multivariable model.246, 
247 In stratified analyses, participants are divided into strata (i.e. sub-groups) of the confounder, and 
the effect of the risk factor is measured within each sub-group. Disadvantages of stratification include 
reduced statistical power due to fewer participants in each sub-group, and possible additional 
confounding if other characteristics are imbalanced between the sub-groups. In Paper I-IV, we used 
multivariable analyses to determine the independent contribution of each risk factor, thereby 
estimating the effect of a risk factor on the outcome, adjusted for confounders.248 It is important to 
note, that even though preventive measures to minimize confounding were applied, we can never rule 
out that unknown confounding factors may be present and lead to residual confounding.249 
In all papers, analyses were adjusted for age, an important confounder for the association 
between the risk factors and outcomes studied. In the analyses, age was used as time-scale, with the 
participants’ age at study enrollment being defined as entry time, and age at the VTE or censoring 
event (i.e. migration, death or study end) being defined as exit time. This is considered the superior 
way of eliminating confounding by age, as compared to age adjustments, if the hazard of the outcome 
is expected to change more as a function of age than as a function of time-on-study.250  
In Paper I, we adjusted for additional risk factors in different models. Sex and BMI are known 
risk factors of both stroke and VTE, and thus important confounders. This is emphasized by the 
substantially attenuated HRs after adjustment. As previously discussed, whether other cardiovascular 
risk factors are independent risk factors of VTE or not is controversial. Adjusting for these risk factors 
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had a marginal impact on the association between stroke 
and VTE, suggesting that they are not confounders or 
mediators for the association. Unfortunately, we did not 
have information on immobilization or infections, which 
we believe are mediators for the association between 
stroke and VTE (Figure 6). If we were able to adjust for 
these variables, we could estimate the direct effect of 
stroke on VTE. However, it is important to remember 
that stroke and VTE can be causally related, even though 
potential mediators exists. Immobilization and infections would not act as confounders for the 
association, but they would be the reason why stroke and VTE are associated.    
In Paper II, we adjusted for age (as time-scale), sex and BMI. These are independent risk factors 
of both atherosclerosis and VTE. Other cardiovascular risk factors were added in the multivariable 
model, however, they did not alter the estimates. In Paper III, the main aim of the study was to 
compare different analyses, not to evaluate the magnitude of the risk estimates. Thus, the analyses 
were adjusted for age (as time-scale) and sex. We found an apparent association between blood 
pressure and VTE, which diminished after further adjustments for BMI, indicating that the association 
was confounded by BMI.  
In Paper IV, we used a case-cohort design in 
which the sub-cohort was randomly selected from the 
full cohort. We adjusted all analyses for age (as time-
scale), sex and BMI, all of which are possible 
confounders for the association between FHMI and VTE. 
The main aim of the study was to assess if the 
association between FHMI and VTE was explained by 
prothrombotic genotypes, i.e. if prothrombotic 
genotypes was a confounder, causing clustering of MI in 
families and VTE (Figure 7). However, when we included the prothrombotic genotypes in a 
multivariable analysis (together with other confounders), the association between FHMI and VTE was 
not affected, suggesting that the prothrombotic genotypes are not confounders and that something 
else drives the association. 
 
Figure 6. Immobilization and infection as 
possible mediators for the association 
between stroke and VTE. 
Figure 7. Prothrombotic genotypes as 
possible confounders for the association 




To investigate whether the effect of one risk factor on an outcome differs across the strata of 
another risk factor, the presence of interaction between the risk factors can be examined.251 
Interaction is also known as effect modification, and the third variable is often called the effect 
modifier.227 Statistical interaction can be evaluated on an additive (absolute risk) and a multiplicative 
(relative risk) scale, depending on the statistical model being used. Furthermore, HRs derived from 
multiplicative models, e.g. Cox regression models, can be used to examine the presence of interaction 
on an additive scale (i.e. biological interaction).252 In Cox regression analyses, the presence of 
interaction on a multiplicative scale can be assessed by entering a product term into the regression 
model.251 If statistical interaction is present, data should be stratified on the effect-modifying variable. 
Even if there was no statistical interaction on a multiplicative scale, there might be interaction on an 
additive scale.251 
 An important assumption of the Cox regression model, which is used in all papers of this thesis, 
is the proportional hazard assumption. This assumption indicates that exposure to a certain risk factor 
is associated with a fixed relative increase in the risk of the outcome of interest compared with a 
reference hazard (i.e. among the unexposed). In other words, the Cox models assume that at any given 
time, the hazard in the exposed individuals is a multiple of the underlying hazard.227 When using age 
as time-scale, a test for proportional hazard assumption will determine if the risk of an outcome among 
the exposed individuals is constant over time (i.e. increasing age), compared with the unexposed. Thus, 
a test for the proportional hazard assumption will also test for interaction with age. 
In Paper IV, we investigated the presence of additive interaction between FHMI and the 
different SNPs on the risk of VTE. Synergism refers to the (positive) interaction of two or more variables 
that combined gives a greater effect than the sum of the individual variables. The presence of 
synergism between two exposures was assessed by calculating the relative excess risk due to 
interaction (RERI), the attributable proportion due to interaction (AP) and the synergy index (SI) 
according to Andersson et al.253 RERI was calculated as HR11 - HR10 - HR01 + 1, where HR10 is the hazard 
ratio for the first risk factor (i.e. FHMI) in the absence of the second risk factor (i.e. prothrombotic risk 
alleles), HR01 is the hazard ratio for the second risk factor in the absence of the first risk factor, and 
HR11 is the hazard ratio when both risk factors are present. AP was calculated as RERI/HR11 and can be 
interpreted as the proportion of cases in the combined group that is due to the interaction between 
the two exposures. Lastly, the SI was calculated as [HR11 - 1]/ [(HR10 - 1) + (HR01 - 1)]. SI can be 
interpreted as the excess risk from exposure to both risk factors when interaction is present, relative 
to the risk from exposure when interaction is absent.252 RERI and AP equal to 0 and SI equal to 1.0 




5.1.6 Missing data 
Despite careful planning and execution of studies, missing data are common in epidemiological 
research, and may introduce bias.255 Data can be missing if participants do not respond to questions in 
the questionnaires, if the equipment used for physical examinations fails, by loss or errors in laboratory 
handling of blood samples, if participants are lost to follow-up, or for other known or unknown 
reasons. The prime concern is always whether the available data is biased or not.255 If an observation 
is missing independent of the unobserved value and other available data, the observation is missing 
completely at random. This would be the case if a blood sample is lost by accident. If the data missing 
is independent on the missing value itself, but not to other variables, the data is missing at random. 
This would be the case if the elderly were more likely to have measured blood pressure than the 
younger population. Finally, data could be missing not at random if it is dependent on the unobserved 
values, for instance, if a question in a questionnaire is (systematically) not answered because it is too 
difficult. Data missing not at random can cause bias.255 There is no optimal way to handle missing data, 
but different approaches exist. Firstly, participants with missing data on covariates can be omitted 
from the analysis. Secondly, participants with missing information can be excluded from the study. This 
gives complete case analyses but can lead to decreased statistical power and selection bias if 
participants excluded differ from those not excluded (which will be the case unless the data are missing 
completely at random). Lastly, it is possible to estimate (impute) what the missing values were, based 
on other known covariates in the study.255, 256 Imputation requires that the data is missing at random. 
 In the present thesis, missing data were handled by omitting participants with missing values 
for variables in the statistical analysis of that specific variable, or by excluding participants with missing 
information from the study. When using the first approach, the number of study participants in each 
analysis varied slightly depending on variables included (< 2%). In Paper II, participants who attended 
the ultrasound examination, but had missing information on IMT or TPA (n=490) were excluded. It is 
uncertain why these measures were missing and how they affected risk estimates. Given the data were 
missing at random or completely at random, e.g. due to defect equipment a certain day, the results 
would not be affected. However, if the data were not missing at random, i.e. dependent on unobserved 
values, results could be biased. This would be the case if, for instance, those with missing information 
were too sick to move to the examination bench, or to obese to obtain valid measurements.  
In Paper IV, we excluded participants with missing values for at least one of the risk alleles 
studies (n=175) and those with missing information on FHMI (n=2,769). As with all laboratory testing, 
there are risks of errors in measurements and handling of the blood samples used for genotyping. The 
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missing values for the SNPs are most likely missing completely at random, i.e. independent of the 
genotypes and other available variables, and exclusion of these participants would not bias the results. 
Assuming the participants with missing information on the FHMI variable did not answer the question, 
simply because they did not know or because they did not have FHMI, the values would be missing at 
random or not at random, respectively. The latter alternative could give biased results, and to 
investigate this possibility, we performed a sensitivity analysis in which participants with missing 
information on FHMI were included in the study and categorized as not having FHMI. The association 
between FHMI and VTE, albeit slightly attenuated, remained when participants with missing data on 
FHMI were classified as having no FHMI, indicating that those with missing information did not 
substantially differ from those without missing information.  
 
5.1.7 External validity 
External validity is the extent to which a study can be generalized to a population.257 External 
validity is of great importance in research where the purpose is to improve public health.258 Internal 
validity refers to the extent to which bias and confounding are minimized so that any difference 
between groups can be truthfully attributed to the exposure.257 Both internal and external validity are 
essential for epidemiological research. There is not external validity without internal validity, but the 
presence of external validity does not guarantee internal validity (i.e. the participants are 
representative of the population, but there is confounding in the study).230 Although RCTs are 
considered to be the best study design for minimizing the effect of bias and confounding, and thus 
maximizing internal validity, the external validity is usually limited due to strict inclusion and exclusion 
criteria.246 Cohort studies are non-experimental, and the absence of random allocation reduces the 
internal validity. However, high-quality cohort studies with well-defined inclusion and exclusion 
criteria, as well as high attendance, enhances the chance of high external validity.  
In the surveys of the Tromsø Study used in the present thesis, the entire or parts of the 
population were invited to participate, and the attendances were high, ranging from 79% in Tromsø 5 
to 66% in Tromsø 6.210 To HUNT 2, all individuals at the age of 20 and older living in Nord-Trøndelag 
County were invited to participate, and the attendance was 71%. The distribution of risk factors and 
incidence of VTE in the Tromsø and HUNT Study are similar to other Western populations, indicating a 
high degree of external validity. As previously noted, the participation rates were lower among those 
< 40 years of age, those > 80 years of age, and among men compared with women, threatening the 
generalizability in these subgroups. In Paper II, we used data from participants attending the second 
and extensive examination. All inhabitants aged 55-74 years and a smaller random sample in other age 
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groups were invited. This weakens the generalizability of the results to the underrepresented age-
groups. Further, cohort studies are prone to non-response bias. Participants may be more health 
conscious than those who did not participate, and institutionalized elderly and ill patients are unlikely 
to attend health examinations. Consequently, participants in cohort studies are usually healthier than 
the general population, and it is likely to assume that this applies to our studies as well. However, as 
discussed previously, non-participation does not seem to introduce substantial bias. The population in 
Tromsø and Nord-Trøndelag are homogenous Caucasian populations,210, 211 with a small Sami minority 
in Tromsø, and our results are likely to be generalizable to other Caucasian populations. However, the 
incidence of VTE and MI,259-261 as well as the distribution of SNPs,262, 263 differs between ethnicities, and 
generalizing our results to populations with other ethnic compositions must be done with caution. 
 
5.2 Discussion of main results 
5.2.1 Ischemic stroke and risk of venous thromboembolism 
Prior to the present thesis, evidence for an association between stroke and VTE was mainly 
derived from small cohort studies on selected populations,9-13, 191, 264, 265 and trials assessing the 
protective effect of different treatment strategies.266-269 The reported incidence of DVT after stroke 
ranges from 4-11% during the first 14 days after the stroke,9, 190, 191, 265 and 15-45% 20-30 days after the 
stroke.9-11 However, these studies screened stroke patients for DVT, and many reported a high 
proportion of asymptomatic DVTs,9-11, 190, 265 and distal DVTs.9, 10, 191, 265 The clinical significance of 
asymptomatic and distal DVTs is uncertain. For instance, proximal DVT is more commonly associated 
with PE than distal DVT,270, 271 and an RCT comparing placebo to LMWH treatment in patients with 
distal DVT found no difference in thrombus extension or symptomatic PE (the trial was terminated 
early due to slow recruitment and expiry of study drug).272 Current guidelines from the American 
College of Chest Physicians recommend that patients with isolated distal DVT without severe 
symptoms or risk factors for extension are followed up with serial imaging after two weeks, and 
recommend anticoagulation only if the thrombus extends.44 Although symptomatic PE occurs in only 
1-5% of patients during the first 14 days after an acute stroke,11, 189, 273 PE may account for up to 25% 
of deaths after acute stroke.189, 192 
The only previous population-based study investigating the association between stroke and 
VTE was a large registry-based case-control study from Denmark, including almost 6,000 patients and 
60,000 controls. The study revealed that patients with a history of stroke had a 4.4-fold (95% CI 2.9-
6.7) increased risk of VTE during the first three months after the stroke. The risk decreased but 
remained slightly elevated (HR 1.18, 95% CI 0.95-1.46), after the initial three months.7 However, the 
54 
 
events in this study were found by searching hospital registries for VTE-related ICD codes without 
further validation, and the study lacked information on possible confounders, including BMI. Thus, we 
cannot exclude that the entire, or parts of the association was non-causal and due to confounding 
factors. 
In Paper I, we reported that subjects who developed ischemic stroke had an increased risk of 
VTE, compared with those without ischemic stroke in the general population. VTE events were 
thoroughly validated and potential confounders were collected at baseline and updated during follow-
up for participants attending more than one survey. The risk of VTE was substantially increased the 
first month after the ischemic stroke, with a multivariable-adjusted HR of 19.7 (95% CI 10.1-38.5). The 
risk of VTE declined to 10.6 (95% CI 5.0-22.5) one to three months after the ischemic stroke and 
remained slightly elevated after three months (HR 1.5, 95% CI 1.1-2.2). Analyses stratified on types of 
VTE displayed a higher risk of provoked than unprovoked events, and provoking factors included, 
among others, immobilization within the last 14 days prior to the event. Risk estimates for DVT and PE 
were approximately the same (HR 19.1 and 20.2, respectively). The association between ischemic 
stroke and VTE remained significant after adjustment for age, sex, BMI and other cardiovascular risk 
factors. 
Our results are in accordance with a registry-based cohort study assessing the association 
between stroke and VTE in the general population published in 2016.274 The study followed 200,000 
stroke patients and a comparison cohort of almost 1 million members of the general population for 
five years and computed cumulative risks, rates, and HRs of VTE. Reported 5-year cumulative incidence 
of VTE was 2.1% (95% CI 2.1-2.2) in the stroke cohort, 2.3% (95% CI 2.2-2.4) in patients with ischemic 
stroke and 1.9% (95% CI 1.9-2.0) in the comparison cohort. 5-year VTE rates were 7.2 per 1,000 PY in 
the stroke cohort and 5.0 per 1,000 PY in the comparison cohort, yielding a HR of 1.5 (95% CI 1.5-1.6). 
The HR of VTE during the initial three months after the stroke was 4.8 (95% CI 4.4-5.2). The HRs were 
higher for PE (5.8, 95% CI 5.2-6.6) than DVT (4.2, 95% CI 3.7-4.7), and higher for provoked events (5.0, 
95% CI 4.6-5.5) than unprovoked events (2.1, 95% CI 1.4-3.0).274 Provoking factors were defined as 
previous cancer or fracture, trauma, surgery, infection, pregnancy, delivery or immobilization within 
90 days before the event. Of note, the stroke patients and VTE events were detected by searching 
registries, and the study had limited information on possible confounders, such as BMI. The specific 
type of strokes were registered (ischemic, hemorrhagic or subarachnoid hemorrhagic), but remained 
unspecified for 45%. The ischemic strokes were associated with a higher cumulative incidence of VTE 
than the hemorrhagic strokes, but the HRs were based on the entire stroke cohort. These limitations 
could, at least to some extent, explain why our study yielded higher risk estimates for VTE.   
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 No recent studies have investigated VTE risk in stroke patients in the absence of anticoagulant 
treatment. As current knowledge and guidelines support routine thromboprophylaxis in hospitalized 
patients with reduced mobility and ischemic stroke,275 it would be unethical to perform RCTs to assess 
the risk of VTE without prophylactic treatment. Although only 37-50% of patients with ischemic stroke 
received appropriate thromboprophylaxis (based on predefined criteria),145, 146 it is reasonable to 
believe that VTE risk would be substantially higher if none received anticoagulation. Furthermore, 
standard management of stroke patients include lipid-lowering treatment with statins and antiplatelet 
therapy with aspirin and/or other antiplatelet agents.276 Statins have been shown to reduce the risk of 
VTE in some,277-279 but not all studies.280, 281 A large meta-analysis published in 2012 did not support a 
large protective effect, but the authors concluded that a moderate reduction in risk could not be ruled 
out.282 Aspirin has previously been associated with decreased risk of recurrent VTE,283, 284 but not with 
decreased risk of incident VTE.285 However, results from a recent RCT found that a more intensive 
antiplatelet therapy reduced the risk of incident VTE.286 Treatment with anticoagulation, and possibly 
statins and aspirin, would underestimate the observed association between stroke and subsequent 
VTE. 
 
5.2.2 Atherosclerosis and risk of venous thromboembolism 
Atherosclerosis is an independent risk factor for stroke and MI, 198-201 and after Prandoni and 
colleagues reported a higher frequency of carotid plaques in patients with unprovoked VTE compared 
with controls, it was hypothesized that atherosclerosis might be the missing link between arterial CVD 
and VTE. The association between atherosclerosis and VTE was later investigated in several studies, 
with different results depending on study design. Case-control studies reported an association 
between atherosclerosis and VTE, and unprovoked VTE in particular.3, 207-209 In contrast, three large 
population-based cohorts found no association, and a cause-specific model excluded MI as a potential 
confounder or mediator.4-6 Several factors may explain the divergent results between cohort and case-
control studies. Firstly, recruitment of controls that are not fully representative of the source 
population from which the cases were derived can lead to overestimation of the true effect. None of 
the case-control studies selected controls from the general population.3, 207-209 Secondly, carotid 
atherosclerosis was defined in different ways in the different studies. For instance, a plaque was 
defined as a protrusion into the lumen of at least 1.5 mm in some studies,3, 5, 209 and as a localized 
thickening of the vessel wall of > 50% compared to adjacent IMT in other studies.4, 208 Lastly, case-
control studies are inherently prone to reverse causation, and it is not possible to determine if 
atherosclerosis caused VTE or vice versa. Although this is an unlikely explanation in the three studies 
in which assessment of atherosclerosis was performed in close proximity to the VTE diagnosis,3, 207, 208 
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it might be the case in the study where assessment of atherosclerosis was done within three years 
from the VTE diagnosis.209 Hald and colleagues calculated and compared risks of MI and VTE associated 
with atherosclerosis to ensure that the measurement and classification of atherosclerosis were 
appropriate. They found an association between atherosclerosis and MI with a similar magnitude as 
shown earlier, but no association between atherosclerosis and VTE.4 The remaining concern was that 
atherosclerosis might have developed over time and that a true association with moderate effect size 
could have been underestimated due to regression dilution bias. The main argument against the cohort 
studies has, indeed, been the long time between the baseline measurements and outcome.287 
In Paper II, we assessed if the negative results in cohort studies were due to regression dilution 
bias by using repeated measurements of participants recruited from the general population. VTE 
events were thoroughly validated and potential confounders were updated during follow-up for 
participants attending more than one survey. In time-varying analyses, we found no association 
between the initiation, presence or progression of atherosclerosis and VTE, and adjustment for 
potential confounders did not alter the results.  Our study confirms the results from previous cohort 
studies and provides further evidence of a non-causal relationship between atherosclerosis and VTE. 
  A recently published study using data from the Tromsø Study assessed whether an incident 
VTE was associated with subsequent formation and progression of carotid atherosclerosis.288 
Participants attending two or more ultrasound examinations in the Tromsø Study were eligible for the 
study, and 150 subjects with incident VTE were identified. Subjects with carotid plaque(s) at the first 
visit had 4.1 mm2 (95%CI -1.7 to 10.0) larger change in TPA between the first and second visit compared 
with subjects without VTE. The association persisted after adjusting for potential confounders, 
including CRP, and after restricting the analyses to VTE diagnosed in the first half of the time interval 
between ultrasound examinations. No association between VTE and subsequent novel plaque 
formation was found.288 The results must be interpreted with caution due to limited statistical power, 
and larger studies are warranted. Nonetheless, increased risk of plaque progression after VTE could 
potentially explain the previously diverging results between study designs (i.e. case-control studies 
detected an increase in atherosclerosis after VTE) and to some extent mediate the association between 
VTE and subsequent risk of arterial CVD. 
 
5.2.3 Shared risk factors for arterial cardiovascular diseases and venous 
thromboembolism  
Of the traditional cardiovascular risk factors, only age and obesity has consistently been 
associated with VTE. Whether other risk factors, such as diabetes, hypertension, dyslipidemia, and 
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smoking, increases the risk of VTE is controversial. As previously mentioned, the majority of studies 
that found an association between cardiovascular risk factors and VTE were retrospective, whereas 
most prospective studies reported no association. While case-control studies are limited by possible 
reversed causation and high risk of recall and selection bias, cohort studies are limited by potential 
regression dilution bias due to a long time between exposure and outcome.  
 In Paper III, we reported that risk estimates for VTE and MI based on a single baseline 
measurement corresponded well with risk estimates based on repeated measurements. Except for 
BMI, none of the atherosclerotic risk factors increased the risk of VTE, neither in the time-fixed model 
based on baseline measurements nor in the time-varying analyses based on repeated measurements. 
The results suggest that regression dilution bias does not explain the lack of association between 
cardiovascular risk factors and VTE in the cohort studies.  
 Our results are in agreement with the majority of previously published cohort studies. Further, 
the results are in accordance with those from a large meta-analysis published in 2017, investigating 
the association between cardiovascular risk factors and VTE. The study by Mahmoodi and colleagues 
was based on data from 9 large cohorts and included approximately 250,000 participants with 5,000 
VTE events.289 In models adjusted for age, sex, and BMI, there was no association between VTE and 
hypertension, hyperlipidemia or diabetes. Current smoking was associated with a 1.2-fold increased 
risk of VTE (HR 1.19, 1.08-1.32), and subgroup analyses revealed that smoking was associated with 
provoked VTE (HR 1.36, 95% CI 1.22-1.52), but not unprovoked VTE (HR 1.08, 95% CI 0.90-1.29). The 
increased risk of provoked VTE is potentially mediated by cancer, which is a well-known risk factor for 
VTE, or hospitalization and immobilization due to other smoking-related diseases, such as MI and 
chronic respiratory illnesses.289 This is supported by the lack of association between smoking and VTE 
in cause-specific analyses, eliminating the mediating effect of cancer and MI.17, 18 In order to assess 
whether the long follow-up in the included studies could have diluted the associations, sensitivity 
analyses with follow-up restricted to five years were performed. Results in the sensitivity analyses 
were comparable to the original analyses with long follow-up. Surprisingly, the meta-analysis found an 
inverse association between systolic blood pressure and VTE. The authors discuss that competing risk 
of comorbid conditions, such as atrial fibrillation, might explain the results as atrial fibrillation is 
strongly associated with hypertension and routinely treated with anticoagulant drugs.289 Nonetheless, 
the study concluded that previously reported associations between cardiovascular risk factors and VTE 
are likely to be non-causal due to confounding.289 
Previous studies have shown an association between FHMI and VTE.26-29 The family history 
itself is not a risk factor but indicates clustering of genetic and environmental risk factors of VTE in 
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certain families. Age and BMI explains some of the association between FHMI and VTE,27 but other 
cardiovascular risk factors have little impact on the association.26-28 Due to the particularly increased 
risk of unprovoked VTE, and that the risk of VTE increased with increasing numbers of affected 
relatives, it was hypothesized that the association between FHMI and VTE was caused by shared 
genetic risk factors. In accordance with previous studies, we found a 1.3-fold increased risk of VTE in 
individuals with a FHMI in Paper IV.  However, the association between FHMI and VTE could not be 
explained by rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG), and rs2036914 (F11), as 
adjustments for these prothrombotic genotypes had a negligible effect on the risk estimates. 
Furthermore, combinations of FHMI and the prothrombotic genotypes had additive effects on the risk 
of VTE. For instance, having both FHMI and rs8176719 (ABO) was associated with a 1.8-fold increased 
risk of VTE, which was equal to the sum of having only FHMI or rs8176719 (ABO). Similar results were 
found for FHMI in combination with the other individual SNPs and the combined 5-SNP score. Our 
results suggest that FHMI and the prothrombotic genotypes are unrelated risk factors of VTE and that 
these prothrombotic genotypes do not affect the association between FHMI and VTE.  
The mechanism(s) for the association between FHMI and VTE remains unknown. Two risk 
factors acting through the same pathophysiological pathway can have both synergistic and additive 
effects on an outcome. For instance, obesity and rs6025 (F5), which are associated with 
hypercoagulability, had synergistic effects on VTE risk.97 Similarly, the risk of VTE in obese women using 
oral contraceptives has been shown to exceed the sum of the effects of the individual risk factors.290 
However, a cohort study of 66,000 genotyped participants found additive effects on VTE risk when 
different prothrombotic genotypes, all causing hypercoagulability, were combined.89 Consequently, 
our results do not allow us to determine the mechanisms behind the association between FHMI and 
VTE and do not exclude the possibility that other unrecognized genetic variants can partly explain the 
association between FHMI and VTE. 
Even though the genotypes studied in Paper IV do not explain the association between FHMI 
and VTE, results from Paper IV and previous studies indicate that genetic risk factors are one of the 
main contributors to the association. In addition, environmental risk factors clustering within families 
may potentially act as confounders or mediators for the association. Although the association between 
FHMI and VTE is independent of traditional cardiovascular risk factors,26-28 other environmental risk 
factors related to both MI and VTE, such as stress and socioeconomic status,20, 178, 291 might partly 
explain the association.   
On the basis of the papers in the present thesis and results from previously published studies, 
it is possible to conclude that, of the well-known cardiovascular risk factors, only age, obesity and FHMI 
are shared risk factors between arterial CVD and VTE. In addition, the association between smoking 
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and VTE observed in some studies seems to be mediated by cancer and other smoking-related 
diseases, such as MI and chronic respiratory diseases. 
 
5.2.4 Possible mechanisms for the association between arterial cardiovascular diseases 
and venous thromboembolism 
The underlying mechanism explaining the observed association between arterial CVD and VTE 
is unknown, but different mechanisms have been suggested. In essence, the association can be non-
causal due to shared risk factors (i.e. confounders), or causal (Figure 8, Panel A). If a causal relationship 
exists, the effect of arterial CVD on VTE can be indirect (i.e. mediated through other factors) or direct 
(Figure 8, Panel B). Furthermore, the association between arterial CVD and VTE can be due to 
confounders, mediators and a direct effect, and thus be partially non-causal and partially causal (Figure 
8, Panel C).  
 The association between arterial CVD and VTE would be non-causal if shared risk factors 
explained the association. As previously discussed, a confounding variable for the association between 
Figure 8. Possible mechanisms for the association between arterial CVD and VTE. Panel A represents a non-
causal relationship caused by shared risk factors (i.e. confounders), and Panel B represents a causal 
relationship. The association that remains after removing the indirect effect caused by mediator(s) 
represents the direct effect of arterial CVD on VTE.  Panel C demonstrate the combined non-causal and causal 
relationship with shared risk factors, mediators and a direct effect of arterial CVD on VTE. 
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arterial CVD and VTE is a variable that is an independent risk factor for VTE, associated with arterial 
CVD and not an intermediate variable between the arterial CVD and VTE. In the papers included in the 
present thesis, we demonstrated that there is no association between atherosclerosis and VTE and 
that BMI is the only traditional cardiovascular risk factor associated with VTE. Thus, atherosclerosis 
and the other cardiovascular risk factors (e.g. hypertension, dyslipidemia, diabetes) do not meet the 
criteria to be confounders, and cannot explain the association. This is emphasized by the small effects 
of adjusting for cardiovascular risk factors and FHMI on the risk estimates for VTE.8, 143, 186 If the 
association between arterial CVD and VTE was explained entirely by cardiovascular risk factors, 
adjusting for these risk factors would completely attenuate the association. Consequently, some of the 
association is likely to be caused by other, unknown, shared risk factors (i.e. residual confounding), 
synergistic effects of known and unknown risk factors, or by indirect or direct factors. 
Furthermore, if shared risk factors were important for the association between arterial CVD 
and VTE, there would be a permanent, and not transient, increased risk of VTE. In fact, the VTE risk 
would be expected to increase over time after diagnosis of arterial CVD, as risk factors tend to 
accumulate over time and age. However, studies investigating the risk of VTE by time since an arterial 
CVD event demonstrated that the VTE risk was substantially increased during the first three to six 
months after the arterial event, but declined rapidly thereafter.7, 8, 185 This suggests that mechanisms 
related to the arterial event itself increase the risk of VTE. 
Several lines of evidence point towards a causal relationship between arterial CVD and subsequent 
VTE. From a clinical and pathophysiological perspective, it is likely to assume that the majority of the 
association between arterial CVD and VTE is caused by mediators. For instance, we know that 
hospitalization and immobilization are important risk factors for VTE,109, 129, 138, 148 and a potential 
consequence of arterial CVD. In accordance with this, some studies have shown that arterial events 
are especially associated with subsequent provoked VTE events.8, 143, 186 Further, Barsoum and 
colleagues found a significant association between MI and VTE in crude analyses (OR 1.84, 95% CI 1.25-
2.71) in a case-control study, but the OR was attenuated to 1.64 (95% CI 1.05-2.57) after they adjusted 
for hospitalization for major surgery or medical illness, and nursing home confinement in addition to 
age and BMI.187 Neurological deficits with accompanying immobilization are common complications of 
stroke,292 and a risk factor for VTE.11, 129 In a population-based case-crossover study, Morelli and 
colleagues investigated stroke and other triggers for incident VTE.293 Stroke was registered in 4.2% of 
the hazard periods (90 days before the VTE event), compared with 0.2% of the control periods (18 to 
6 months), resulting in a 20-fold increased risk of VTE (95% CI 8.3-48.1). The risk was attenuated to 6-
fold (95% CI 1.6-22.1) when immobilization and infection were taken into account, and a mediation 
analysis revealed that 68% of the total effect of stroke on VTE risk was mediated by immobilization 
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and infection. In a study by Sørensen and colleagues, the risk estimates of VTE four months to five 
years after MI and stroke were 1.01 (95% CI 0.78-1.31) and 1.18 (95% CI 0.95-1.46), respectively. After 
five years, the risk was similar for MI and stroke patients (RR of 1.3).7 The higher long-term risk in 
stroke patients might reflect the increased risk of prolonged immobilization due to paralysis or paresis. 
Supporting this hypothesis, studies have shown that different measures of stroke severity are strongly 
associated with VTE risk,11, 190 and that most DVTs after stroke affects the paretic leg.9 
However, studies have demonstrated an increased risk of unprovoked VTE after arterial CVD as 
well, and some studies found similar risk estimates for unprovoked and provoked VTE.7, 185 Thus, it is 
unlikely that hospitalization and immobilization explain the entire association between arterial CVD 
and VTE. Other medical complications are frequent among MI and stroke patients,294 and potential 
mediators for the association between arterial CVD and VTE include infections due to prolonged 
hospital stays,141, 295 heart failure,129, 148, 296 atrial fibrillation,46 and surgery (e.g. coronary artery bypass 
grafting).139 Infections have been shown to increase the VTE risk independent of immobilization,141, 295 
suggesting that other factors, such as local inflammation and activation of coagulation, contribute to 
the increased risk of VTE. While both heart failure and atrial fibrillation has the potential to induce 
stasis and subsequent VTE, it has also been suggested that atrial fibrillation can lead to right-sided 
atrial thrombi that can dislodge and cause PE.46 This hypothesis is supported by the particularly 
increased risk of PE after MI,7, 8, 185 and it might (partly) explain why up to 50% of patients with PE do 
not have concurrent DVT.1, 2, 45   
The direct effect of arterial CVD on VTE would be the association that persists after adequate 
adjustments for confounders and mediators. However, indirect and direct effects can be hard to 
distinguish from each other, especially for multifactorial diseases without a specific and known 
mechanism, such as VTE. For the association between arterial CVD and VTE, the direct effect would be 
the basic pathophysiological mechanisms in which arterial CVD leads to coagulation activation and 
thrombus formation. For instance, studies have demonstrated alterations in concentrations of pro- 
and anticoagulant proteins in the acute phase of ischemic stroke,297, 298 and a bidirectional association 
between inflammation and coagulation can possibly induce thrombus formation.299 However, it might 
be difficult to differentiate whether these alterations are a result of the arterial event itself or other 
medical complications following the arterial event.  
Finally, the association between arterial CVD and VTE might be a result of medical surveillance 
bias. As previously discussed, it is a type of bias that can occur if an exposure leads to closer surveillance 
and an increased probability of detection of an outcome. We cannot exclude that patients with MI and 
stroke are under stronger surveillance, and are more likely to undergo diagnostic procedures for DVT 
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and PE, than the general population. Including only symptomatic VTE events will, to some extent, 
reduce the risk of this bias.  
The association between arterial CVD and VTE is a result of a complicated interplay between non-
causal and causal mechanisms. To unravel the total causal effect of arterial CVD on VTE, analyses must 
be adjusted for confounders, and to investigate the direct effect of arterial CVD on VTE, analyses must 
be adjusted for confounders and mediators (see Figure 8). However, this might be difficult as there 
may be reasonable doubt as to whether a variable is in the causal pathway between arterial CVD and 
VTE or not, and because a variable might be a confounder and a mediator. For instance, one can argue 
that obesity increases the risk of both arterial CVD and VTE, and thus be a confounder for the 
association. Conversely, one can also argue that obesity is a result of an inactive lifestyle, a possible 
consequence of an arterial event. In this case, obesity is in the causal pathway between MI and VTE, 
and can thus be classified as a mediator. Nevertheless, the most important initiative to improve patient 
care is to acknowledge arterial CVD as a risk factor for VTE, to avoid complications of arterial CVD 
related to increased VTE risk, and to give appropriate anticoagulation in situations where 
thromboprophylaxis is warranted. As current data on the prediction of VTE in stroke patients are 
scarce, better knowledge regarding risk factors and triggers for VTE in stroke patients are important to 














• Subjects who developed ischemic stroke had an increased risk of VTE compared with those 
without stroke in the general population. The risk of VTE was especially high during the first 
three months after ischemic stroke and declined rapidly thereafter. Ischemic stroke yielded 
higher risk of provoked VTE than unprovoked VTE, and adjustments for cardiovascular risk 
factors did not attenuate risk estimates. This suggests that mechanisms or conditions related 
to the stroke itself contribute substantially to the association between ischemic stroke and 
VTE 
 
• Carotid atherosclerosis, measured by IMT and TPA in time-varying analyses, was not 
associated with future risk of VTE. Furthermore, there was no association between plaque 
initiation or plaque progression and VTE. Our findings suggest that atherosclerosis is not an 
intermediate for the association between arterial CVD and VTE 
 
• We found that risk estimates for VTE and MI based on a single baseline measurement and 
time-fixed analyses corresponded well with risk estimates based on repeated measurements 
and time-varying analyses. Except for BMI, none of the cardiovascular risk factors were 
associated with VTE, suggesting that the lack of association between cardiovascular risk factors 
and VTE in previous prospective cohort studies cannot be explained by regression dilution bias. 
For MI, the difference between risk estimates from the time-fixed and time-varying analyses 
was greatest for variables that changed much during follow-up and for variables with strong 
associations with MI 
 
• The known association between FHMI and VTE was not explained by rs8176719 (ABO), rs6025 
(F5), rs1799963 (F2), rs2066865 (FGG) or rs2036914 (F11). Combinations of FHMI and the 
prothrombotic genotypes displayed an additive effect on VTE risk, indicating no biological 





7. Final remarks and future perspectives 
The findings in this thesis support a strong association between stroke and subsequent VTE. The risk is 
especially high during the first three to six months after the stroke, indicating that factors related to 
the stroke itself increase the risk of VTE. Thus, it is important to avoid complications of the stroke 
related to increased VTE risk, such as immobilization and infections, and to use thromboprophylaxis. 
Current international and national guidelines recommend prophylactic-dose LMWH or intermittent 
pneumatic compression stockings in patients with acute ischemic or hemorrhagic stroke and restricted 
mobility.275 Unfortunately, evidence suggests that these guidelines are not routinely followed. 
Although rates are somewhat higher in most European countries,145 only 37-50% of stroke patients 
worldwide receive appropriate thromboprophylaxis.145, 146 To improve patient care, it is important to 
increase the rates of appropriate use of thromboprophylaxis in stroke patients and to develop 
prediction models to accurately discriminate between patients at high and low risk of VTE. 
 Our results support the findings from previous cohort studies reporting that there is no 
association between atherosclerosis and VTE. Thus, atherosclerosis cannot explain the association 
between arterial CVD and VTE. Furthermore, we have reported that, among the well-known 
cardiovascular risk factors, only age, obesity and FHMI are associated with VTE. In addition, there 
seems to be an association between smoking and provoked VTE which is mediated by cancer and other 
smoking-related diseases.289 The association between arterial CVD and VTE persists in analyses 
adjusted for cardiovascular risk factors, suggesting that there is a causal relationship between arterial 
CVD and VTE. Further research to unravel the mechanisms behind the association between arterial 
CVD and VTE are warranted to understand the complex interplay between shared risk factors, 
mediators and direct effects.  
 MI, stroke, and VTE are the three most common cardiovascular diseases, with a high risk of 
mortality and disability. Shared risk factors are important targets for interventions, as there is great 
potential to decrease the burden of several diseases. Obesity is, as discussed in this thesis, a shared 
risk factor for arterial CVD and VTE. In 2016, more than 1.9 billion adults were overweight and over 
650 million adults were obese,116 and the prevalence of both overweight and obesity is increasing.116, 
300 A high proportion of arterial CVD and VTE events can be attributed to obesity,118, 301, 302 and 
interventions to reduce obesity are important to reduce the large impact of MI, stroke, and VTE at an 
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